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This workbook is part of a series
intended to educate program plan-
ners, managers, staff and other de-
cision-makers about the evaluation
of services and systems for the treat-
ment of psychoactive substance use
disorders. The objective of this se-
ries is to enhance their capacity for
carrying out evaluation activities. The
broader goal of the workbooks is
to enhance treatment efficiency and
cost-effectiveness using the informa-
tion that comes from these evalua-
tion activities.
This workbook (Workbook 5) is
about cost analysis. In general terms,
it involves evaluating the use of resour-
ces ‘spent’ on the treatment of people
with substance use disorders
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What is a cost
evaluation?
A cost evaluation assesses the use of re-
sources ‘spent’  on the treatment of people
with PSU disorders.  There are three differ-
ent levels  of costing studies.   Instructions for
how to complete each of these types of cost
evaluations are located later in this workbook:
• Evaluating resource use within one par-
ticular agency
• Comparing the costs of different interven-
tions across two or more agencies
• Wider studies of the fuller social cost
consequences of different interventions
Cost evaluations can be done by different
groups of people with different purposes.
Different groups include treatment services,
the funders of the services, wider regulatory
authorities, or supporting agencies.  Treat-
ment providers may be most interested in
tracing their own resource use, and/or  the
consequences of any changes in service pro-
vision.   The funders of services or regula-
tory authorities may be interested in  com-
parisons between agencies.  In contrast, a
wider society perspective attempts to exam-
ine all the resource consequences, regard-
less of  who bears these costs. Taking a so-
cietal perspective can considerably extend
the work required, but allow for better com-
parison across agencies.
Why do a cost
evaluation?
The economic technique of cost evaluation
is one of the tools available to help choose
wisely from a range of alternatives and to
design and implement efficient programs.
Cost evaluations  assess the gains and the
costs of carrying out a set of activities.  The
purpose of this analysis is to identify ways to
do the most with a limited budget.  In other
words, it is designed to identify the most ef-
ficient approach.
Resources available for treating those with
PSU disorders are limited in all countries.  A
number of different groups, including treat-
ment providers, want to monitor resource
use.  In addition to such monitoring, they want
to understand the relationship between levels
of activity and resource use and costs.   Ques-
tions might include:  how much will costs in-
crease if the number of outpatient visits rises?
What would be the fall in costs and resources
if the number of PS users treated decreases?
Other questions assess the overall level of re-
sources and how this relates to population
needs; the distribution of resources among
different groups of the population with vary-
ing problems, and the efficiency of resource
use within individual services.
Questions
might include:
how much will
costs increase
if the number
of outpatient
visits rises?
What would be
the fall in costs
and resources
if the number
of PS users
treated
decreases?
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Before doing a cost evaluation, it is im-
portant to review Workbook 1 of this
series, which outlines general steps to
evaluation planning. In addition, review
these three common steps within each of the
different types of costing studies: (1) identify
the resource use for the appropriate unit of
activity; (2) measure resource use per activ-
ity level; and (3) value this unit of activity.
After this section, three specialised ‘how to’
sections are presented, for the three differ-
ent levels of evaluations:
• Evaluating resource use within a particu-
lar agency
• Comparing the costs of different interven-
tions across agencies
• Wider studies of the fuller social cost
consequences of different interventions
How to do a cost
evaluation: general steps
There are three broad cost groups of PSU
interventions:
• the direct costs of service provision
• the costs to the individuals or their families
• the costs (or averted costs) falling on other
agencies as the result of the ‘treatment’
episode
The direct costs of services can be further
broken down into:
• capital costs - building, equipment furni-
ture and fittings
• building related expenditure - heating,
lighting, property taxes, maintenance
• staff costs
• other service related expenditure - sta-
tionary, telephone, travel costs, etc.
• overhead costs - management and admin-
istrative expenses often shared across
interventions or services
These types of costs have different relation-
ships with the level of activity of the service.
Fixed costs (e.g., building rent, heating, etc.)
do not vary with the level of activity. In con-
1. Identify the costs associated
with PSU services
trast, other costs are variable, for example,
the travel costs associated with caring for
clients at home will vary directly with the num-
ber and location of these clients. Staff costs
(e.g., salaries) tend to be of a semi-fixed na-
ture and are important because for most PSU
services they make up most of the costs of
service provision. Staff may undertake some
additional ‘caseload’ but there are limits to
the numbers any one person can handle.
Expansion of the service at this point would
require some extra staff.
The mixture of fixed and variable costs de-
termines how average costs change as levels
of activity change. For example, a service
with a large fixed cost element, say a large
stand-alone residential unit, would yield a high
cost per inpatient stay if occupancy of the
unit was low. The average cost would fall as
the unit approaches capacity and would rise
again if some new accommodation was
needed. Marginal cost is the cost at any point
of providing one extra unit. It is important
for planning purposes to calculate marginal
as well as average costs.
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The costs borne by individuals and their fami-
lies will vary across health care systems.
Some care has to be taken to count genuine
resource use, but not simple transfers. For
example, individuals may receive benefits
from the state or an insurance scheme if they
are participating in treatment. This is not a
resource but a transfer between one group,
the taxpayer or other members of the insur-
ance scheme, to those who are ill. The re-
source loss in this situation (especially where
inpatient or residential care is concerned) is
that of the ‘productivity’ or leisure time of
the individual. These indirect costs may be
borne by the individual or the employer. There
is considerable discussion about the role of
such indirect productivity losses in economic
evaluations. Generally, the advice is to show
these costs as a separate item so that overall
results can be calculated with and without
allowance for these costs (Drummond et al.,
1987). Individuals may have direct costs of
treatment such as out of pocket expenses,
and the time costs of treatment which will
not be included in any traditional, service-
oriented tracing of resource use. Some treat-
ment, particularly inpatient treatment may in-
volve individuals? loss of working or leisure
time. As well as these tangible items there
are more intangible elements to interventions.
These include the ‘pain, grief and suffering’
of the PS user and their families.
The last group of costs are those borne by
other agencies. Some interventions may re-
quire input from other social, welfare and
health care agencies. On the other hand, some
interventions may reduce future demands for
such services provided by other agencies.
These are the type of costs which are identi-
fied for social cost type of study.
The first case example at the end of this work-
book (French and McGeary) presents a
structured and scientifically-based instrument
for estimating costs of treatment services. This
instrument, the DATCAP, includes costs from
a variety of relevant categories.
2. Measure resource use
per unit of activity level
Units of activity have to be measured along
with the resources needed to deliver them.
The ‘units’ of activity will be determined by
the purpose of the study, available data and
the type of intervention being delivered. Units
could be in many forms. Some common ex-
amples would be counselling visits, inpatient
stays, assessment interviews, or some divi-
sion per time period such as cost per type of
care per hour or per week. If comparisons
are being made across different organisations,
it is essential that units of activity are mea-
sured in a standardised way.
If the purpose of the study is to provide some
general idea of overall resource use within a
treatment agency, then direct costs of provi-
sion would generally be measured on annual
data. However, capital costs (such as build-
ings or equipment) will not necessarily be in-
curred in that year, although they are one of
the resources being used to provide care for
PS users. The value of these assets can be
included by estimating their actual value or
replacement cost, and spreading this cost
over the expected lifetime of the asset. Build-
ings are often estimated to have a ‘life’ of 60
years, whereas other capital equipment is
estimated to have a life of five to ten years
depending on the item. Using an interest of
6%, for example, a building worth $1 million
would have an annual value of $61,876 (the
calculation can be made using standard in-
terest rate tables).
Units could be
in many forms.
Some common
examples
would be
counselling
visits, inpatient
stays,
assessment
interviews, or
some division
per time period
such as cost
per type of care
per hour, per
week etc.
10 Evaluation of Psychoactive Substance Use Disorder Treatment
WHO/MSD/MSB 00.2f
The choice of the time period over which
some of the wider consequences of an inter-
vention are measured is not clear cut. If, af-
ter treatment, individuals quit smoking or re-
duce drinking or other PSU, the potential
savings in consequent health care costs could
be spread over the rest of their lifetime. How-
ever, direct observation and measurement of
such costs would not be possible. In some
cases epidemiological modelling can be em-
ployed to calculate these potential savings in
health and other welfare costs. However, if
reliable models are not available, measure-
ment may be curtailed to some arbitrary pe-
riod after the end of the intervention.
The DATCAP case example located at the
end of this workbook demonstrates how the
basic cost estimate can be expressed in a
variety of units: total annual cost per ser-
vice, weekly cost per client, and cost per
treatment episode. In the case example, con-
clusions differed depending on the unit of
activity.
Most agencies will have some information
about costs in their routine accounting infor-
mation system. You can use this information
to value your units of activity.
As mentioned earlier, the value of capital
items such as buildings or office equipment
may be the actual value or replacement costs
and this cost would be spread over the ex-
pected lifetime of the asset. Buildings are of-
ten estimated to have a ‘life’ of 60 years,
whereas other capital equipment is estimated
to have a life of five to ten years depending
on the item.
In most instances, people, buildings, and ve-
hicles have multiple functions. It is important
to identify cost sources that are shared by
other activities, and to find a reasonably ac-
curate way of dividing these costs among the
various activities. This process is called cost
allocation.
Examples of Cost Allocation:
1 One room in a PSU treatment centre (an-
nual cost estimated at $3,000) is used for
a prevention programme. The room is
900 square metres and the whole centre
is 20,000 square metres. The annual value
of the space for the prevention
programme is: 900/20,000 x 3,000 =
0.045 x 3,000 = $135
3. Value this unit of activity
2 A nurse receives $900 per year. In the
past year, 20,000 patients were seen at
her treatment centre and 1,000 were pa-
tients in the prevention programme. The
allocation fraction is 0.05 (1,000/
20,000). This means that $45 of her an-
nual salary should be allocated to preven-
tion programme costs.
For PSU services, another common valua-
tion problems is the use of volunteers to de-
liver part of the treatment programme. Vol-
unteers may involve some direct costs to the
services, for example, in reimbursing their
expenses, training and administrative costs,
but their labour time does not appear in the
accounts. However, volunteers are also con-
tributing time which may have an alternative
value, for example, in work for a wage or
leisure activity. One method would be to
value volunteers? time by some market wage
rate, say, the unskilled wage rate or a rate
based on their past or current occupation. It
is also clear that volunteer resources can not
be assumed to be directly substitutable with
time from the professional workers. They may
be less flexible in how much time they can
offer to the service and they may choose to
avoid some of all the activities of paid staff.
As with many other aspects of costing meth-
odology, there is no single answer. In gen-
eral, most studies would give volunteers an
initial zero value but explore the impact on
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results of the cost analyses by valuing their
time by different amounts.
The costs of resources which would be
used in the future are generally valued
less than those in the current period. This
is called discounting and is a means of
bringing all costs to a present value.
Costs are usually discounted at the pre-
vailing general interest rate. Drummond
and colleagues (1987) provide tables
that provide the conversion from future
amounts to this present value, given the
interest rate.
The top-down
approach
involves
estimating the
total resource
use for any
organisation for
a specified
period and then
allocating the
resource use to
the units of
activity.
The bottom up
approach
involves directly
recording the
resource use for
each
intervention
including the
appropriate
share of
overhead and
capital costs.
One additional point:
Allocating costs to units of activity
top down or bottom up?
There are two basic methods for determin-
ing the direct cost of any intervention: ‘top-
down’ and ‘bottom-up’. The top-down ap-
proach involves estimating the total resource
use for any organisation for a specified pe-
riod and then allocating the resource use to
the units of activity. This method ensures all
the observed resources are allocated to the
activities of the unit.
The bottom up approach involves directly
recording the resource use for each interven-
tion including the appropriate share of over-
head and capital costs. With good resource
management and time monitoring systems,
this approach can give accurate estimates of
costs for individual units of activity (e.g., cost
per hour of assessment) or clients (e.g., av-
erage cost per client). This methodology will
only value the resources that are used and
any ‘spare’ capacity would not be valued.
In this situation the total value of resources
could be below those shown in the accounts.
Conversely, if staff are working more than
their contracted hours, the total amount of
resources may be above the official budget.
Ideally, costing studies should use the bot-
tom-up approach for the costs of major in-
terest. However, in practice it may only be
possible to use a top-down approach in situ-
ations with limited data. Some costs, par-
ticularly overheads and capital, may always
be allocated in a top-down fashion.
In some instances, both a top-down and
bottom-up approach may be needed. A
simple example would be a service deliver-
ing just one type of standardised interven-
tion. In this case a simple top-down estimate
of average cost per unit of activity would be
straightforward to calculate from the estimate
of all resources and all activity. However, this
method would not indicate whether there was
any variability in the costs. It may be, for
example, that younger clients are in receipt
of more counselling sessions than older cli-
ents. To examine this variability, some bot-
tom-up costing would be needed.
The next four sections provide more detailed
information about different types of cost
evaluations.
Ideally, costing
studies should
use the bottom-
up approach for
the costs of
major interest.
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The process of doing cost evaluations within
one agency can be broken down into seven
main steps:
• outline of the purpose of the study
• describe the service organisation and the
interventions under review
• identify the resources needed to deliver
the interventions
• collate the existing data sources
• develop an analysis plan
• conduct new data collection
• conduct full analysis
The information provided in these steps is
complementary to that outlined in Workbooks
1 and 2 of this series. Be sure to review
Workbooks 1 and 2, if you have not al-
ready done so, follow the steps outlined in
those workbooks.
Evaluation type 1
How to do cost
evaluations within
one agency
For agencies
with no
current cost
information, a
first step may
be to devise
unit costs for
different
interventions
offered
There may be several reasons for undertak-
ing a cost evaluation within a particular
organisation. For agencies with no current
cost information, a first step may be to de-
vise unit costs for different interventions of-
fered. This may be undertaken with a nar-
row focus, tracing only the resources directly
used in the interventions offered by the
agency. This would normally be undertaken
during a set period of time, (usually a year),
and with data retrospectively. One different
kind of this type of study would be to inves-
tigate the cost across clients rather than units
of activity. However, this may need a differ-
1. Outline the purpose of the study
ent time period and be undertaken prospec-
tively to trace the use of resources for a group
of clients. This type of study would usually
be undertaken as part of an economic evalu-
ation (Workbook 8), even if some data were
available through patient billing systems.
Other studies may be undertaken with spe-
cific changes in service provision in mind. For
example, you may want to predict the con-
sequences of increasing or decreasing the
frequency of maintenance therapies. Or, you
may be contemplating more drastic re-
organisations of the whole agency. For this
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The next step in any costing study is to ex-
amine the service and provide some break-
down of the activities. Development of
programme logic models will help identify the
specific services and activities to be costed.
The purpose of the breakdown of activities
within specific services is two-fold. First, it
provides an overall framework over which
the resources needed for the whole service
can be allocated. The second purpose is to
determine the units of activity for costs to be
calculated. The detail of your breakdown will
be related to the purpose of your study.
Have you completed a programme logic
model, as described in Workbook 1 of this
series? Retrieve and review your programme
logic model now, or complete one if you have
not already done so.
type of study, it is necessary to relate current
resources with the units of care that can be
delivered and how changes in different
programmes may interact with one another.
This requires knowledge of the potential
caseload of different workers taking into ac-
count both the contact time with clients and
the non-contact time, for example, in co-
ordinating with other agencies or writing up
case notes. Planning such studies requires
close partnership between the clinical staff
and those doing the costing study.
2. Describe the service and
interventions
The next step is to consider what types of
resources are required to deliver each type
of care. As described earlier, the components
will be staff time, consumables, space and
building related expenditure, and administra-
tive and management expenses. The
consumables will include items such as post-
age, telephone, stationery as well as medi-
cation costs, testing procedures and travel
costs directly linked to client care. Providing
care can involve a long list of different items
including insurance, training, and recruitment
expenditure.
3. Identify the resources needed for
each intervention/unit of care
When free
resources are
included, you
will be costing
the service
from the
societal
perspective.
When they are
excluded, you
will have
adopted the
agency
perspective.
Some items should be included even
though they may not appear on the bud-
get. For example, treatment services may
have a number of ‘free’ resources, in free
or subsidised property, or seconded staff
from other welfare agencies or volunteers.
Although these resources are free in finan-
cial terms, they are not without value. Also,
services may not be replicated at the initial
cost and failure to take account of free re-
sources in planning could have financial
implications.
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Most agencies will have some data already
available, for example, hours of work, clas-
sification and costs of staff. You can use this
database for your data analysis.
The ability to use current information to al-
locate resource use across activities will de-
pend in part on how the organisation man-
ages its finances. In some agencies, there
will be clear cost accounting across activi-
ties and some confidence may be placed
on the current tracing of resources if ‘cost
centres’ are in operation. However, some
care must be taken with such divisions. For
example, in one study of a local agency
(Godfrey at al., 1995), it was found that the
whole of the director’s salary was allocated
to the core services even though the direc-
tor also managed the work within prisons.
This was a historical allocation based on
sources of funding rather than actual re-
source use.
It is also necessary to examine current data
sources for levels of activity. In some sys-
tems, detailed utilisation of services may be
kept with details of each client. In general,
however, some data will be available on to-
tal levels of activity of a unit, for example,
the total number of clients seen, the total num-
ber of counselling appointments, etc. The
more detailed the activity database, the more
detailed can be the cost analysis.
The final source of information is records of
individual staff’s working practices. Some will
only be assigned to certain activities while oth-
ers may work in a number of areas. Some
organisations will have time budgets for their
staff but, as with other budgets, there is a need
to check that resources are used in line with the
budgets. The cost of staff should include all
employers’ costs such as payroll taxes and
pension contributions. Other expenditures are
usually available from the expenditure accounts.
4. Collect and collate available data
The more
detailed the
activity
database, the
more detailed
can be the cost
analysis.
5. Develop an analysis plan
There are four main aspects of planning the
analysis of a costing study: choice of units of
activity; measuring and valuing of resources;
allocation mechanisms for related resources
to units; and choice of simulations from the
calculations.
The choice of units will relate to the purpose
of the study, the activity breakdown, and vi-
ability of collecting data. Some of the gen-
eral measurement and valuation issues have
been discussed in preceding sections. You
will need to decide whether to value re-
sources by the actual value in the service or
by some national average rate. Staff, build-
ings and many other resources may have dif-
ferent values according to the locality of the
service. National valuation figures may be
useful for generalising results, but for pro-
viders and funders of services, local varia-
tions in the cost of resources will be impor-
tant. In general, it is useful for all costing
studies to report resource use in physical units
(e.g., 3 buildings: 20,000 square metres) as
well as their value.
The next step of the analysis plan is to con-
sider the means of allocating resources to
units of activity and the mixture of top-down
and bottom-up methodology to be adopted.
This plan will depend on the type of service
and the information available on suitable
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allocators. For most PSU treatments, staff
resources make up the majority of the reported
resources. As discussed earlier, percentages
of total time taken in face-to-face contact (or
if available the total time including non-con-
tact) is one of the most efficient ways to allo-
cate staff expenses. Similarly, building and
space-related expenditure such as rent (capi-
tal cost), maintenance, heating, lighting, clean-
ing, etc., could be allocated by the proportion
of floor area used in different activities.
The main part of the analysis plan for most
studies is to obtain some current average cost
per unit of activity, for example the cost per
counselling appointment. Where available, it
may be possible to examine how different
units of activity are combined for the cost of
an intervention, for example, cost per client
for an outpatient programme. These aver-
age costs, however, will depend on the overall
level of activity of the unit and may not re-
main the same if activity rises or falls. Calcu-
lating the marginal, or extra, costs for an in-
crease or decrease in activity is a useful
addition to the analysis. For example, Brad-
ley et al (3) calculated the cost for one addi-
tional client and an extra 25 clients for a
methadone treatment programme.
All cost calculations require assumptions to
be made, and the analysis plan should include
what attempts are to be made to assess the
effects of changing these assumptions. Using
the results in a number of simulations of treat-
ment changes may also be part of the analy-
sis plan. This sort of exercise may include
some of the factors which may influence the
future costs of delivering PSU treatments and
types of interventions.
One of the main purposes of the analysis plan
is to consider whether existing data are suffi-
cient to fulfil the objectives of the study. If
not, some plan has to be made to collect new
data. This may be in the form of an observa-
tional study. For example, staff in settings
such as an inpatient facility could be observed
for a set period and resource use directly
noted. This could form the basis for a de-
tailed bottom-up costing study. There are
problems with this type of data collection. It
can be expensive, people may behave dif-
ferently if observed, and the process may
seem threatening to staff or disruptive to the
care process.
An alternative is to use questionnaires or dia-
ries with staff and/or clients. It is the alloca-
tion of staff time across the different activi-
ties performed which is most often missing.
Asking staff to note use of time in a diary for
a set period is a reasonable way to under-
stand how services work and give some in-
formation about the resources required for
different activities. It is particularly useful for
examining the amount of non-contact time
required for each treatment event. The first
step is to explore all categories of staff time
so that the full working day can be accounted
for by the staff. For example, it is important
to include training time, team meetings, su-
pervision, case note writing, liaison work and
travelling time. In some cases, it may also be
useful to note the resources used by clients
either by asking them to complete diaries or
attaching recording forms to case notes.
There are similar problems with data collec-
tion by survey as those encountered by ob-
servational study. Although the method may
not be so intrusive, there are problems with
validating self-reports. Often this will need
to be examined in relation to other sources
of data such as the level of activity. The tim-
ing of surveys are also important. For ex-
ample, while a two-week survey may yield
sufficient data, there would be problems if
the weeks chosen fell, for example, in a main
holiday period. In most cases, some cross-
6. Conduct new data collection
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checking can be made with other sources.
For example, total yearly time available can
be calculated from the contracted hours mi-
nus holidays and average time off for sick-
ness.
Gathering information requires resources.
One question is whether these costs should
be included as part of the costs of treatment.
Again, there is no universal answer. Part of
any good quality intervention should be sys-
tems to ensure quality. Monitoring systems
including resource tracing can be seen as part
of normal care and hence costs included.
Similarly, there is a need to include some
development costs in any situation. However,
other costing studies may be undertaken as
part of a wider research exercise, and if the
costs of data collection are for research pur-
poses, these costs should be excluded.
Only with the previous steps in place can the
full analysis be undertaken. It is useful as part
of the analysis to build in a number of checks
on the calculations. For example, do the data
on staff time correspond to the total number
of hours available according to their con-
tracts? Are resources being ‘over’ or ‘un-
der’ used and hence is the current level of
activity sustainable for the future? Are the new
7. Conduct full analysis
data collected in line with staff expectations
or have some resources, including time, been
omitted? It is important to state in the dis-
cussion of the results what items were ex-
cluded from the analysis.
For more details on data analysis and re-
porting of results, see Workbook 2 of this
series.
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Evaluation type 2
 Data need to be generated in a similar form across
agencies. The ease of this process will depend on
the comparability of existing data between agen-
cies and developing comparable new data collec-
tion methods. This may be easier when compari-
sons are being made between stand-alone services
than where the PSU treatment is being undertaken
in a larger organisation, for example a hospital (Bra-
dley et al., 1994). To facilitate comparability, it may
be necessary to develop a checklist of the resources
required for each unit or type of intervention to
check that all have been included.
It also is easier if programmes of care are deliv-
ered according to a similar protocol across agen-
cies. While there is a need to have comparable
methodology, it could be counter-productive to
have an overly rigid system of accounting for every
type of resource use. It may be impossible given
current information systems for allocations to be
made at the level of detail of all individual resources
and a rigid system may lead to inaccuracies. Again,
the needs depend on the purpose of the study and
the detail of the analysis of any figures required. A
more feasible approach may be to aim for broad
comparability as a first round and then undertake
more detailed analysis where large discrepancies
between agencies delivering seemingly similar in-
terventions or activities are found.
There are also particular valuation issues to be ad-
dressed when making comparisons over more than
one agency. Local valuations of the same amount
of resources may vary. It would be expected that if
there is any substitutability of resources these local
variations in values may affect the treatments of-
fered. However, the purpose of the study may not
be to compare the values but the resource use it-
self. In that circumstance, figures giving values alone
may be misleading.
You should work with each agency and devise a
system which will meet the overall aims of the study
and also provide useful information to individual
agencies. Unless the agencies see the purpose of
the costing exercise and not feel overly threatened
by the analysis, data reliability and continued data
collection cannot be guaranteed. Over large ar-
eas, such as a country, such detailed work may
not be possible and there may be a reliance on
charges or expert opinion on treatment costs (see,
for example, Holder et al., 1991).
Another application for information on resource
use across agencies is to examine the distribution
of total resources compared to population needs.
For this purpose, the focus is on measuring and
valuing all resources rather than accurately mea-
suring the resources needed for each intervention.
This type of study may take place at a more ag-
gregate level and consist only of broad average
costs. However, the loss of detail often means that
no sensible comparisons could be made across
services.
Data need to be
generated in a
similar form
across agencies.
How to do cost evaluations
across different provider
agencies
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People with PSU disorders can have a num-
ber of health, social and legal problems.
These problems can incur costs to a range
of agencies and other members of society.
Wider social cost studies attempt to trace out
the full resource implications of PSU treat-
ment (French et al., 1994; Godfrey, 1994).
While these studies are commendable in their
efforts to be comprehensive, they are typi-
cally too complicated to conduct and have
been criticised on a number of methodologi-
cal issues.
The second case example located at the end of
this workbook (by Williams and Gerstein), de-
scribes an evaluation of wider social costs and
benefits for treatment programmes in the State
of California, USA. Evaluators examined so-
cial costs and benefits of PSU treatment, such
as criminal activity and employment earnings.
Evaluation type 3
How to do cost
evaluations of wider
social costs of PSU
interventions
PSU treatment can involve costs for clients,
families, other agencies and the rest of soci-
ety. However, the treatment may also reduce
future health and other welfare costs. A large
range of effects could potentially be identi-
fied for inclusion in these types of studies.
For example, some studies have been un-
dertaken from the narrow focus of the health
care sector, comparing the costs of PSU
treatment to reduced future health care costs
attributed to that treatment (for example,
Holder and Blose, 1987; Goldman et al.,
1991). While such studies may be useful for
advocacy purposes, there is a problem if com-
parisons are being made across programmes
because the one with the highest savings in
future health care costs may not necessarily
be the one with the highest total benefits, in-
cluding those to the individual client.
Most studies adopt a societal perspective and in-
clude only resource costs. Others, however, have
attempted to trace out the impact on state finances
or the taxpayer (see, for example, Gerstein et al.,
Identifying the range of costs
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1994). The taxpayer perspective will focus on
who bears the costs. Thus, some transfer pay-
ments may be included to trace who loses and
who gains as a result of the treatment process.
The main areas considered are:
• health and other welfare care use
• criminal costs
• productivity loss
Health and welfare use could include addi-
tional costs as a result of treatment or fu-
ture savings as a consequence of a success-
ful treatment. Lost productivity has already
been mentioned. As well as any losses as a
consequence of treatment per se, there is
also the potential effect on future job pro-
ductivity.
In general,
however,  self-
reported
outcomes have
to be used.
These are
usually valued
by taking an
average cost
figure from
some official
source of data.
The tracing of resource use after treatment usu-
ally requires a comparison at a client level. In
other words, you need to trace a cohort of cli-
ents. However, this raises a major measure-
ment problem of attributing any future costs to
the intervention itself and not to other factors.
Because most existing studies have used a com-
parison of costs before and after treatment for
the same individuals, the data are subject to
biases the decline in resource use and costs may
not be directly attributable to the treatment in-
tervention. Another major problem of these
studies is the lack of information about the so-
cial costs of those not in treatment.
With such wide effects to measure, there has
to be some compromise with accuracy. In
some systems, actual health care costs (or at
least charges) can be traced. In general, how-
ever, self-reported outcomes have to be used.
These are usually valued by taking an average
cost figure from some official source of data.
Some potential and costly effects, for example,
a road traffic accident, may be so low in inci-
dence that either a very large sample or a long
time period would be needed to get an accu-
rate measurement. In some cases, epidemio-
logical risks are known and, therefore, future
probable consequences can be modelled via
computer analyses.
A particular evaluation problem occurs with
measuring the costs of criminal activity. The
response to crime from the criminal justice
system is one cost. More debatable is
whether the value of goods stolen should be
included as a social cost. It could be argued
that the value of the goods in itself is not a
resource loss. These goods are not lost but
are ‘transferred’ to others in society. The
resource costs of such crime are fear and
other intangible costs, the criminal justice re-
sponse and extra resources devoted to se-
curity measures which may result from high
levels of crime. As with other controversial
areas, a final decision will be linked to the
study purpose. For purposes of
generalisability, it is useful to present results
which are capable of re-analyses for those
who want to make other assumptions.
The measurement and evaluation of lost pro-
ductivity poses other problems. These indi-
rect costs can be large for long residential
and in-patient care and overshadow all other
costs. However, evaluing the time spent in
treatment, as if someone was fully employed,
is likely to overestimate the resource loss to
society. Also, it can rarely be assumed that
successful treatment will result in large pro-
ductivity gains if there is a high level of un-
employment in the economy.
The final issue is the time period over which
such studies are conducted. Some effects could
be life long, although the longer the period from
the intervention the more difficult is it to attribute
any resource change to the intervention rather
than to some other factor. In general studies
are limited to relatively short periods of fol-
low-up (e.g., one to three years).
Measurement and evaluation issues
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Its your turn
Put the information from this workbook to
use for your own setting. Complete these
exercises below.
Remember to use the information from
Workbooks 1 and 2 to help you complete a
full evaluation plan. Review that information
now, if you have not already done so.
1 Decide the scope of your study. Will you
evaluate costs within an agency, across
several agencies, or evaluate wider so-
cial costs?
• Within an agency
• Across several agencies
• Wider social costs
2 Determine what ‘unit’ of activity you will
measure. Your unit of activity level will
depend largely on your research ques-
tion (see Workbook 1). It could be a
specific component of the programme:
common examples would be counselling
visits, inpatient stays, assessment inter-
views, or some division per time period
such as cost per type of care per hour,
or per week.
3 List programme cost sources that you
want to evaluate. If evaluating services
across agencies, decide the common
measurement(s) you will use. Meet with
planners from the other agency(ies) to
achieve consensus on the evaluation
methods.
For right now, do not assign specific mon-
etary amounts to these sources — just
record the different areas. We have
started the list as an aide for you. Cross
out the sources that do not apply to your
situation, and add others that are not al-
ready listed.
Capital costs
• building
• equipment
• furniture
• vehicles
Building related expenditure
• heating
• lighting
• property taxes
• maintenance
Staff costs
• salaries
• fringe benefits
Other service related
expenditure
• stationary
• telephone
• vehicle operating costs
• travel costs
Overhead costs
 • management and administrative
expenses
4 Assess the data that are available to you
from existing sources, such as patient bill-
ing records, payroll accounts, etc. Deter-
mine what information you have available,
and what other information you will still
need to find out. If you need to collect
additional data, decide what method you
will use to do this. Review Workbook 2
to help you choose an appropriate data
collection measure.
5 Use your list of your programme’s cost
sources to begin to assign specific mon-
etary amounts — per unit of activity level.
Consider capital costs, cost allocation, vol-
unteers, and discounting in your calcula-
tions. If you do not have all the informa-
tion right now, make note of what you
know and also make note of what you
need to find out later to complete the list.
Decide whether you will use a top-down
and/or a bottom-up approach for estimat-
ing costs. Consider your research re-
sources and your available data while
making this decision.
21Workbook 5  •  Cost Evaluations
WHO/MSD/MSB 00.2f
Example Case:
Capital costs
• building (building value/60 years — then divided by 4 because
prevention programme occupies only 25% of building) 15,000
• equipment (equipment value/10 years) 5,000
• furniture (furniture value/10 years) 2,000
• vehicles (vehicle value/10 years) 1,000
Building related expenditure
• heating 500
• lighting 200
• property taxes 1,000
• maintenance 300
Staff costs
• total prevention staff
salaries plus benefits 120,000
Other service related expenditure
• stationary 400
• telephone 1,200
• vehicle operating costs 670
 • travel costs 2,000
Overhead costs
 • management and
administrative expenses 80,000
Total 1996 costs 229,270
A research group was interested in measuring the cost of the prevention component of their
programme during 1996. They compiled the following list:
22 Evaluation of Psychoactive Substance Use Disorder Treatment
WHO/MSD/MSB 00.2f
In this workbook, we have outlined the
basic principles and practices of cost
evaluations within PSU services and sys-
tems. In undertaking cost evaluations, it
is essential that you pay close attention
to the principles and practices of plan-
ning and implementation as outlined in
Workbooks 1 and 2. Trade-offs have to
be made as to the rigour with which you
collect and analyse information to an-
swer your evaluation questions, and the
resources you have available. You must
strive to achieve the best possible infor-
mation with the time and resources avail-
able to you. You must carefully docu-
ment the limitations of your findings and
conclusions. With these principles in
mind, you will be able to undertake prac-
tical and useful cost evaluations within
your treatment service or system.
After completing your treatment evaluation,
you want to ensure that your results are put
to practical use. One way is to report your
results in written form (described in Work-
book 2, Step 4). It is equally important,
however, to explore what the results mean
for your programme. Do changes need to
happen? If so, what is the best way to ac-
complish this?
Return to the expected user(s) of the re-
search with specific recommendations
based on your results. List your recommen-
dations, link them logically to your results,
and suggest a period for implementation of
changes. The example below illustrates this
technique.
Based on the finding that operating costs
in programme A are 20 percent lower
than operating costs of programme b, yet
serve the same number and type of cli-
ents, we recommend that programme ad-
ministrators study information about cli-
ent outcomes in these two settings. If
outcomes are similar, it may be feasible
to adopt the practices of programme A
on a larger-scale basis.
Remember, cost evaluations are a critical
step to better understanding the day to day
functioning of your PSU services. It is im-
portant to use the information that process
evaluations provide to redirect treatment
services. Through careful examination of
your results, you can develop helpful rec-
ommendations for your programme. In this
way, you can take important steps to cre-
ate a ‘healthy culture for evaluation’ within
your organisation.
Conclusion and a practical
recommendation
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The following cases present evaluations re-
lated to different aspects of cost evaluation.
In the first case, Michael French and Kerry
Anne McGeary describe the rationale and
development of a cost data collection instru-
ment called the Drug Abuse Treatment Cost
Analysis Program (DATCAP). The second
case, written by Ellen Williams and Dean
Gernstein, presents an evaluation of wider
social costs and benefits for PSU treatment
in California, USA.
The DATCAP was developed and refined
over a five year time period. The evaluators?
goal was to create a structured and scientifi-
cally-based instrument for estimating the eco-
nomic cost of PSU treatment services, thus
providing a tool for making comparable cost
estimates across agencies and over time. The
DATCAP includes cost estimates from a
variety of categories, such as major equip-
ment, contracted services, and personnel.
‘Free resources’ such as volunteers also are
included at estimated fair economic value.
The basic unit of analysis is total cost for an
individual treatment programme, but this fig-
ure can be transformed to other units such
as weekly cost per client. Examples of evalu-
ations using the DATCAP are provided.
The California cost evaluation (CALDATA)
was undertaken to provide scientific justifi-
cation for continued PSU treatment costs.
This was a broad-based evaluation, exam-
ining costs of several treatments as well as
the wider social impact of delivering these
treatments in terms of clients? criminal ac-
tivity, hospitalisations, employment earnings,
and substance use. Evaluators used com-
puterised record abstraction and client in-
terviews to collect data. Results were gen-
erally supportive of PSU treatments,
indicating that the economic benefits of PSU
treatment outweighed the costs of provid-
ing treatment.
Authors of both cases point out the im-
portance of obtaining reliable data for cost
evaluations. In some settings, a majority
of cost data are compiled already for ac-
counting purposes. In other settings, no
such data are available, or may be insuffi-
cient and/or unreliable. Evaluators must
consider always whether they believe that
existing data is sufficiently reliable to use
in their cost evaluation. If not, alternate and
more reliable sources of data should be
considered.
Comments about
case examples
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Who was asking the
question(s) and why
did they want the
information?
Drug abuse treatment providers need to
know the cost of the services they provide.
Indeed, continued public and private fund-
ing is now being linked to cost and outcome
measures, and providers can use financial
data to improve organisational efficiency.
One of the dangers, however, of promoting
cost studies for treatment programs is that
most program staff are not technically pre-
pared to perform cost analyses and little user-
friendly information is available to offer them
assistance. Furthermore, not all cost meth-
ods are consistent, which can lead to non-
comparable estimates that are difficult to use
for policy or planning purposes. Our paper
provides treatment programs with a much-
needed technical assistance tool. Specifically,
we present a structured and scientifically-
based instrument for estimating the economic
Case example of a
cost evaluation
The authors alone are
responsible for the
views expressed in this
case example.
* This paper is a
revised and condensed
version of an earlier
manuscript by French
M.T., Dunlap L. J.,
Zarkin G. A., McGeary,
K.A. and McLellan A.
T. (1997).
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cost of treatment services ? the Drug Abuse
Treatment Cost Analysis Program
(DATCAP). The components of this instru-
ment are outlined and findings from three
actual case studies are presented.
Program evaluation research has a long tra-
dition in health care with several evaluation
methods that are scientifically developed and
empirically tested. Evaluation of substance
abuse treatment programs is, however, a rela-
tively new endeavour. Although the demand
for such analysis is extensive, the availability
of techniques and methodologies has been
lacking. The recent increase in the demand
for these evaluation studies has fostered the
growth of distinct ways to conduct cost analy-
ses. However, a lack of standardisation in
cost analysis for the substance abuse field
has led to an uneven set of initial studies that
have varied considerably in terms of meth-
ods, terminology, and perspectives (e.g.,
Cruze, et al., 1981; Harwood, et al., 1984;
Rice, et al., 1991; Annis, 1986; McLellan et
al., 1983; Holder and Blose, 1992;
McCrady et al., 1986; NIDA, 1987;
Horgan, 1991; CALDATA, 1994; Finigan,
1996). Consequently, most of the early stud-
ies cannot be compared across programs or
to more recent studies because the measures
are not equivalent (French, 1995; Dunlap and
French, In Press). As more economic evalu-
ations are conducted, there will be an in-
creasing need for comparable estimates of
treatment services for treatment planning and
policy recommendations. Performing a cost
analysis is the first step in any complete eco-
nomic evaluation of treatment interventions
(Gold, et al., 1996; French, 1995). If the cost
analysis is unstructured or methodologically
flawed, then a subsequent cost-effectiveness
analysis, medical cost-offset analysis, or ben-
efit-cost analysis will be compromised. Given
the critical importance of following a struc-
tured and methodologically sound approach
for estimating treatment cost, the primary
purpose of this paper is to introduce a
standardised data collection procedure that
can meet these objectives.
The Drug Abuse Treatment Cost Analysis
Program (DATCAP) has evolved over five
years of research into a flexible cost instru-
ment that follows economic principles, pro-
vides useful information to treatment pro-
grams and funding sources, and is user
friendly. One of DATCAP’s most appealing
features is that the data and cost estimates
from any particular program can be directly
compared with similar data and estimates
from other programs, and for individual pro-
grams over time.
The discussion and analysis that follow pro-
vide a conceptual framework for economic
cost estimation and offer practical guidance
on how to use the DATCAP instrument for
substance abuse treatment programs. First,
economic cost estimation through the
DATCAP instrument is discussed followed by
the evolution of the instrument into its present
form. Second, we review each section of the
instrument and describe the information nec-
essary to answer pertinent questions. The fi-
nal sections outline current applications and
limitations of DATCAP1  along with policy
implications and recommendations.
What resources were
needed to develop and
implement this
instrument?
This instrument was developed over five
years and with the assistance of several fund-
ing grants. The programs usually invest ap-
proximately two to three day to assemble the
information and complete the instrument.
1
 For a more extensive
and detailed discus-
sion of the DATCAP
instrument see French
et al., 1997.
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How were the data
collected?
Conceptual framework for cost
estimation
The following five elements are important steps
to ensure reliability in cost estimation.
1 Select a single measurement perspective that
is flexible, standardised, and widely sup-
ported (e.g., economic (opportunity) cost).
2 Focus on a single analysis perspective that
is workable, standardised, and policy
driven. In our case we use the treatment
program as our perspective for analysis.
3 Define a fixed set of cost categories that
are consistent with standard economic
theory and used in other cost analyses.
4 Develop and define a standard set of ques-
tions to arrive at cost estimates within each
category.
5 Propose a relatively narrow range of ac-
ceptable sources for the resource use and
cost data that will be used to calculate the
estimates.
6 Describe and follow a consistent method
for estimating costs for each category of
data used.
The elements noted above can be considered
strategic steps in the collection of reliable and
accurate treatment cost estimates. Each step
has been incorporated into the DATCAP in-
strument. By clearly defining and following
these perspectives and steps, the reliability of
the cost estimates will be maximised. The re-
mainder of this section explains these steps in
greater detail and how they are
operationalized through DATCAP.
Regarding the actual content and organisation
of DATCAP, the instrument reflects standard
economic resource and cost variables that
have appeared throughout the economic lit-
erature for many years (Mishan, 1975;
Sugden and Williams, 1979). Specifically, the
heart of economic cost analysis is opportunity
cost or opportunity value (Drummond,
Stoddard, and Torrance, 1987). Economists
measure the cost of program resources based
on the value of those resources in their next
best use, while accountants and practitioners
in most other disciplines typically estimate pro-
gram costs based on actual expenditures
(Horngren, 1982). The opportunity cost
framework is operationalized in the DATCAP
instrument, which fosters standardisation and
comparability.
The concept of opportunity cost and other
economic principles related to DATCAP are
best explained in the context of examples.
Recall that economic costs hinge on the op-
portunities that are foregone by using a re-
source. Thus, the economic cost of utilising a
treatment counsellor for 40 hours per week
over the course of a year is the value of the
next best use of that counsellor’s time. Ac-
countants, on the other hand, would normally
view the cost of this counsellor as the salary
that she earned for a year of work. If the
counsellor’s salary was equal to the next high-
est value of her time, then economic cost and
accounting cost are equivalent. However, if
the counsellor was being paid a salary below
the rate that she could obtain in the next best
use of her time, then economic cost would be
greater than accounting cost. Since competi-
tive organisations do not typically acquire re-
sources at a rate that is greater than market-
clearing prices, accounting costs are almost
always less than or equal to economic costs.
Economists are more concerned with oppor-
tunity costs than accounting costs because
program evaluations require standardisation.
For example, it would be unfair to compare
the accounting costs of program A with pro-
gram B when program A received significant
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donated resources and program B had to
pay full market prices for essentially the
same resources. If both of these programs
used exactly the same resources within a
particular year, program A would show a
much lower accounting cost than program
B, but the economic costs would be equal.
In comparing the programs, the economic
approach is the superior method because it
is not distorted by program-specific differ-
ences in resource costs. In addition, pro-
gram replicability would require information
on economic costs rather than accounting
costs because economic costs are a pure
measure of resource value.
Another important issue for cost estimation
is the perspective of the analysis. Depend-
ing on the study objectives, costs can be
estimated from the perspective of treatment
clients, treatment programs, third-party
organisations (e.g., insurance companies),
or society as a whole. Each perspective re-
quires a different data collection process and
estimation strategy. For example, treatment
clients incur costs related to travel time, lost
work time, and child care. Costs to the
treatment program include personnel time,
equipment, and facility rental. The DATCAP
instrument adopts a treatment program per-
spective for data collection and analysis be-
cause programs require financial information
for funding and performance measurement.
Resource allocation rules are best developed
for treatment programs; the treatment program
is generally the unit for licensing and quality
assurance evaluation, and the program is typi-
cally the contracting unit.
The final conceptual issue involves the actual
presentation of economic costs. Most cost
analyses will be based on annual costs be-
cause of record-keeping convenience and
because one year of time represents a rea-
sonable period to reflect a pattern of resource
usage. The first variable that can be computed
from annual data is total annual cost. This
measure includes the cost of all treatment ser-
vices and operations throughout the year. To-
tal costs can be in turn divided into fixed and
variable components. Fixed costs such as
physical capital and facilities are invariant to
the number of treatment clients served. Vari-
able costs such as personnel vary with the size
of a treatment program.
Information on total annual cost and client
caseflow can be combined to estimate average
annual costs such as the cost of treating one
client continuously for one year. Average cost
estimates are useful because data are normalised
so that treatment programs that vary widely in
size can be directly compared. For example,
program A could have a much higher total an-
nual cost than program B, but a smaller aver-
age cost due to the fact that these costs are
distributed over a much larger client base. This
concept is referred to as economies of scale.
The total cost variable is an important mea-
sure for understanding the financial implica-
tions of program expansions. Specifically,
marginal cost represents the incremental
change in total cost due to a small change (e.g.,
one client) in program production or output.
Depending on program operations, marginal
cost may be very low up to a threshold level
of additional clients (e.g., 10 or 15 clients)
and then increase sharply because a new
counsellor is needed or facility space is re-
quired as additional clients are enrolled in
the program.
In summary, DATCAP collects resource
use and cost data to enable the estima-
tion of both economic and accounting
costs since each measure serves a dif-
ferent purpose. The unit of data collec-
tion and analysis is the individual treat-
ment program rather than the client, the
insurance company, or the taxpayer. In-
formation from DATCAP can be used to
estimate the total annual cost for a par-
ticular program, along with measures of
average and marginal cost. Lastly, the
basic structure of the DATCAP instru-
ment has a long history in the economics
literature, which strengthens the compa-
rability and the ability to generalise the
findings.
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2
 Given the precise
formatting and length
of DATCAP, it would
be difficult to
reproduce the
instrument within this
manuscript. However,
the latest version of
the DATCAP
instrument and User’s
Guide is available from
either Dr. French or Dr.
McGeary at the
University of Miami.
Please direct all
inquiries (e-mail
preferred) to Dr. French
or Dr. McGeary at the
address on the first
page of this paper.
Design and organisation
of DATCAP2
DATCAP is usually administered as a
face-to-face interview for treatment pro-
vider sites that collects and organises detailed
TABLE 1:  Resource use and cost categories in the DATCAP instrument
Personnel Supplies Major Contracted Buildings Miscellaneous Not recorded
& materials equipment services & facilities resources elsewhere
Direct Medical Office Laboratory Total space Utilities Goods
salaries furniture
Fringe Office Computers Repairs/ Total usable Insurance Services
benefits maintenance space
Volunteers Housekeeping Electronics Security Rate Taxes Contracts
of use
Food Medical Housekeeping Rental rate Telephone
 Printing
Residential Advertising
information on the resources used in treat-
ment operations and the associated economic
costs (e.g., French, Dunlap, Zarkin, and Galinis,
1994). Table 1 presents the broad resource
categories included in DATCAP along with
specific items.
These categories are generally set up to en-
compass the range of economic costs asso-
ciated with many treatment programs. It is
left to the program director to itemise re-
sources and (with the assistance of an expe-
rienced administrator) estimate economic
costs within each category. In some cases
we have provided a list of items that may be
appropriate only for a specific type of treat-
ment program. Therefore, items may be
added or omitted based on the program’s
needs. To ensure that the reliability of the
instrument is not compromised by allowing
this flexibility, the sections were developed
to include cross checks so that the data are
accurate and consistent. The strategy here is
to maximise reliability of information by (1)
defining and standardising a fixed number of
questions to use in determining each cost cat-
egory; (2) facilitating the interpretation of the
question; and (3) recommending the types of
data that will be acceptable to answer those
questions. In general, the economic cost data
are collected from general ledgers, personnel
reports, expenditure reports, equipment req-
uisitions, and inventory reports rather than from
budgets because budgets do not always co-
incide with actual resource use.
In focusing on the total economic costs in-
volved with treatment, DATCAP also asks
program directors to list free and/or
subsidised resources used in treatment pro-
vision (e.g., volunteer workers). The market
value of free/donated resources can be
estimated by multiplying the share of a re-
source used by the drug abuse treatment pro-
gram by the estimated fair-market value of
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the resource. For example, the estimated
market value of a volunteer worker is the
salary he or she could earn in a paid position
doing similar tasks. Thus, the costs reported
from DATCAP should include the values for
all the resources used by a program in pro-
viding treatment regardless of whether the
program actually incurred an expense for the
resource. We believe that this costing method
provides a realistic measure of economic cost
and more accurate comparisons between
programs because it does not distort the true
resource cost for programs that have better
access to free, donated, and/or subsidised
resources. The data collection process for
DATCAP also includes questions on program
revenues and client case flows. This infor-
mation provides a useful link between the
costs of the program, treatment services, and
the sources of funds for the program (French,
et al., 1996). By collecting resource use and
cost information we are able to gain a better
understanding of treatment operations, which
will enable a full economic evaluation.
For each program, it is desirable to con-
duct a half-day site visit to administer the
DATCAP instrument. However, much of the
data collection can be done prior to the visit.
Approximately one week before the site
visit, the instrument can be sent to the
programs with instructions on how to com-
plete as many data categories as possible
before a trained data collector arrives. Data
collection often continues for a few days
after the site visit to ensure that complete
and accurate information is provided for all
sections of the instrument.
How were the data
analysed?
As noted earlier, DATCAP is a program-
level instrument and data collection would
normally occur annually at each program.
The specific variables that will be available
from the instrument are diverse. For
example, DATCAP information allows us
to calculate the average cost of servicing
one client continuously for one year at each
program. This variable normalises the annual
cost information so that average cost
estimates can be compared across
programs of different size and durations of
treatment for the average client. Once again,
these ratios convert the aggregate
information into units that can be compared
across programs for a standard period of
time. The diagram below is an example of
the type of information that can be compiled
from DATCAP data.
•  Clients served
•  Average length of stay
•  Static caseload
•  Licensed capacity
• Range of services
• Type of program
• Equipment
•  Office supplies
• Capital
• Facility
• Rent
• Contr. services
Client/Program Opportunity costs
Characteristics Fixed    Variable      Revenue
• Personnel
• Equipment
• Medical supplies
• Physician services
• Advisory board
• Federal
• State
• Local
• Client fees
• Private grants
• Donations
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What did they find out?
Recent case studies using DATCAP
Table 2 reports the results of three case study
cost analyses that were completed late in
1996. The economic variables that are cal-
culated for each site are total annual eco-
nomic cost, weekly economic cost for a typi-
TABLE 2.  Characteristics and costs of case study Treatment Programs (1995)a
A  Private, not-for-profit Methadone maintenance 150 559 1,973,601 67.90 7,662
B  Private, not-for-profit   Outpatient drug-free  16 165   718,921 83.79 1,341
C  Private, not-for profit   Outpatient drug-free  22 148   618,748 80.40 1,778
aThe cost measures are reported in 1995 dollars.
bEconomic cost per treatment episode may not exactly equal the product of weekly cost per client and average length
of stay due to rounding.
Prog. Financial
Structure
Modality
Total
annual
economic
cost
Average
length of
stay
(Weeks)
Average
daily
census
Economic
Cost Per
Treatment
Episode b
Weekly
Economic
Cost per
Client
cal client, and economic cost per average
treatment episode. All three programs are
private, not-for-profit entities. Generally,
public programs may have slightly lower eco-
nomic costs compared to private, not-for-
profit programs. However, if public programs
are heavily subsidised at the federal, state,
or local level, their accounting cost would be
significantly lower than a similar private pro-
gram in the same modality.
For our case studies, we found the two out-
patient drug-free programs to have similar
average lengths of stay C 16 and 22 weeks.
These two programs were comparable in size,
based on an average daily census of 165 and
148 clients. However, a substantial difference
of about $100,000 in total annual economic
cost is present between the two programs.
This total cost differential leads to some dif-
ferences in other economic cost measures such
as the average weekly cost to service one cli-
ent and the average cost for a treatment epi-
sode. Higher total and average costs for Pro-
gram B relative to Program C can be partially
explained by significant relocation and reno-
vation expenses incurred by Program B dur-
ing the relevant time period.
Cost differences are also found when com-
paring estimates across modalities. For ex-
ample, Program A is a methadone mainte-
nance clinic with an average daily census of
559 clients and an average length of stay of
around 150 weeks. Given these relatively high
caseflow statistics, the estimated total annual
cost at Program A was considerably higher
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than Program B or C. The estimated cost per
treatment episode C weekly economic cost
per client multiplied by the average daily cen-
sus C was also relatively high at Program A
because methadone maintenance clients typi-
cally have a longer length of stay. However,
the weekly cost per client for Program A is
lower than the other two programs. There-
fore, the methadone maintenance program
distributes its higher economic costs over a
larger number of clients. In the field of eco-
nomics this concept is known as economies
of scale. While the purpose of these case stud-
ies and cost estimates is to illustrate the type
of information that can be derived from
DATCAP, comparisons with other DATCAP
findings can be made by referring to French et
al. (1996).
Table 3 presents a different perspective on
resource use by showing the distribution of
costs across resource categories. As ex-
pected, labour is clearly the dominant resource
with cost shares around 50 percent or higher.
Building and facility costs account for a large
proportion of Program A’s total annual op-
portunity costs. This situation is unusual be-
cause Program A is using two very large fa-
cilities to accommodate their large case flows.
The building and facility costs for Program
B and C are more representative of an av-
erage distribution. Additionally, we found that
the distribution of costs across resource cat-
egories both within or across modalities is
TABLE 3.  Distribution of costs across resource categories*
Prog.
Financial
Structure Modality
Major
Equipment
Contract
Services
A Private, Methadone Maintenance 62 3 20 5  4 6
Not-for-Profit
B Private,   Outpatient Drug-Free 58 2  5 3 30 3
Not-for-Profit
C Private,   Outpatient Drug-Free 71 5  4 8  4 8
Not-for Profit
*Percentages may not add to 100 due to rounding.
Supplies
and
Materials
Buildings
and
Facilities
Other
ItemsLabour
highly program specific. Program B had a large
distribution of costs for major equipment. This
is primarily due to the renovation and relocation
expenses mentioned earlier. Program C had
much lower major equipment purchases, and
a significantly larger percentage of Program
C’s resources were allocated to labour com-
pared with Program B. Otherwise, the small
variation in the distribution of costs across pro-
grams is consistent with the organisational
structure of most treatment programs and the
reliance on labour-derived services.
Potential limitations of the DATCAP
The information reported in Tables 2 and 3
represents a significant improvement in the
way treatment cost data have been collected,
analysed, and reported. However, a few po-
tential limitations are still present with the
DATCAP approach to cost estimation. For
example, some programs were not able to
locate actual records to describe all re-
sources used by their clinics. In these cases
we had to rely on recall approximation and
expert judgement. Obviously, reliability
cannot be as high under these circum-
stances. Second, to estimate the opportu-
nity cost of some resources we sampled
local markets to estimate existing prices
(e.g., real estate markets for rental rates of
commercial property). These calculations
may have some sampling error because we
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generally relied on a small number of vend-
ers or agents for price quotes. Lastly, the
most important contribution of DATCAP to
treatment research is still limited by the rela-
tively small sample of cost and effective-
ness studies that have been completed to
date. When standardised cost estimates are
available from a larger sample of programs
we will have much more accurate informa-
tion on treatment cost and cost-effective-
ness. The method and data summarised here
are certainly informative, but it would be
incorrect to assume that the cost estimates
are representative of all or even most sub-
stance abuse programs in the United States.
How were the
results used?
Few studies have examined the costs of
treatment programs, especially alcohol,
drug, and mental illness treatment programs.
The shortage of useful policy-relevant in-
formation in this area is especially un-
fortunate for federal and state agencies
that are responsible for the allocation of
public funds to treatment programs. These
agencies often make policy decisions us-
ing outdated cost estimates and rough av-
erages in their decision rules for Block
Grants and other disbursements to indi-
vidual programs. The lack of financing and
cost information is also unfortunate for in-
dividual drug abuse treatment program di-
rectors as they try to develop strategies in
anticipation of changes in health care
markets and financing; and more generally
to improve the operation and efficiency of
their clinics.
In addition to the lack of cost and financing
information noted above, proposed inter-
national health care reforms threaten to
place new restrictions on availability of funds
for substance abuse services, causing chal-
lenges to the financial viability drug treat-
ment programs. In this changing environ-
ment, it is unclear whether treatment
programs will receive more attention and
possibly more funding from policy makers.
However, policy makers lack critical
information on the concerns and potential
responses of substance abuse treatment
programs to proposed changes.
We have tried to take the first step in ad-
dressing a part of the information gap faced
by agencies at all levels, and by treatment
program managers, by developing
DATCAP. DATCAP provides timely, ac-
curate, and comparable cost estimates for
all of the purposes and constituents noted
above. This ensures that resource alloca-
tion decisions are made more reliably and
accurately at the federal, state, and local
levels. By focusing on economic cost, pro-
gram administrators will be able to better
estimate the opportunity costs of their ser-
vices and identify which funding sources
hold the most promise for continued growth.
As more programs use DATCAP, more
accurate and informative comparisons can
be made across patient types, treatment
modalities, and variations in therapeutic
services.
Results from these types of cost analyses
will provide program directors, other policy
makers, and researchers with useful and
current information on the cost and finan-
cial structure of a range of drug abuse treat-
ment programs. Our past experience show
that program directors who completed
DATCAP were grateful to have quantita-
tive information. These directors have unani-
mously stated that the benefits of having
these cost estimates significantly outweighed
the investment of their time and other
resources to assemble the data and partici-
pate in the data collection exercise.
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Its your turn
What are the strengths and the weaknesses of the presented case example? List three
positive aspect and three negative aspects:
Strengths of the case study
1
2
3
Weaknesses of the case study
1
2
3
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Who was asking the
question(s) and why
did they want the
information?
The California Drug and Alcohol Treatment
Assessment (CALDATA) evaluated publicly
supported drug and alcohol treatment
programs delivered in the state of California
from 1991 to 1992 . The project involved
an analysis of costs and benefits that applied
to all drug users discharged from the major
types of programs in the state. Before
CALDATA, every U.S. study was somewhat
limited either by the treatment facilities being
selected for convenience or the study focus-
ing on only some subgroup of participants.
For example, researchers might study pa-
tients in facilities that co-operated because
of professional affiliation with the research
team. Other studies originated because of
interest in special treatment philosophies or
approaches—studying the effectiveness of
medical, psychological, or social treatment
models or of various combination ap-
proaches at facilities chosen for special pur-
The California Drug and Alcohol
Treatment Assessment (CALDATA):
The costs and benefits of treatment
by
Ellen Williams
97 Hickory Ridge Road
Conway, Massachusetts USA 01341
Telephone 413-369-4983
and
Dean R. Gerstein
NORC/Washington DC Office
1350 Connecticut Avenue, Suite 500
Washington DC USA 20036
Telephone 202-223-6040
Case example of a
cost evaluation
The authors alone are
responsible for the
views expressed in
this case example.
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poses. Evaluations based on these limited
samples, were suggestive but could not be
confidently projected to treatment outcomes
or costs in U S. facilities at large, or in some
large subdivisions like the state of California
(with one-eighth of the U.S. population.)
Andrew Mecca, Dr. P.H., Director of the
California Department of Alcohol and Drug
Programs (ADP) in the administration of
Governor Pete Wilson, had early experience
overseeing drug treatment programs in Viet-
nam. He had seen outcomes that told him
that “treatment works” — drug and alcohol
recovery programs changed the behaviour
of their participants for the better and were a
benefit to society. However, early in the
1990s, Dr. Mecca also knew that his
department had no arguments that would rig-
orously justify use of scarce public funds to
pay for treatment costs. A statistical analysis
of the treatment experience of a representa-
tive sample of clients was missing, even
though California, given its population size
and the scope of its economy, is larger than
many nations. No other U.S. state had un-
dertaken such a study, nor was such infor-
mation available on a national level. Early in
the 1990s, events came together to make the
CALDATA analysis possible.
First, California had a database newly in
place in 1991 that accounted for treatment
programs. The California Alcohol and Drug
Data System (CADDS) collected key data
on admissions and discharges from all drug
and alcohol treatment facilities legally required
to report to ADP. Also in 1991, the National
Opinion Research Center at the University
of Chicago (NORC) received a federal
award to design a survey gathering treatment
outcome data from a nationally
representative sample of persons discharged
from drug and alcohol treatment facilities and
to make a cost/benefit analysis of the results.
By 1992, the research team at NORC had
brought the design of the national treatment
outcome study to completion, but a
reorganisation of the federal agencies post-
poned the data collection phase. When Dr.
Dean Gerstein, the Principal Investigator on
the team outlined the study to a meeting of
the state directors of Alcohol and Drug Pro-
grams as a preliminary step to gaining their
co-operation, Dr. Mecca saw the opportu-
nity to fund a survey for the state of Califor-
nia alone that would anticipate the postponed
national study, answering questions about the
effectiveness, the costs, and the social utility
of drug and alcohol treatment programs that
were of critical importance to California.
Using federal funds earmarked for local
evaluation research, ADP commissioned
NORC to adapt the national design to gather
data only in California and in 1994, published
the resulting CALDATA analysis of the ef-
fectiveness and the social costs and benefits
of drug and alcohol treatment at the state
level in the U.S. The report set forth the data
from interviews with 1,850 individuals re-
cently receiving treatment for drug and alco-
hol problems in facilities publicly supported
by the state of California.
What resources were
needed to collect
and interpret the
information?
Conduct of a study of this scope required
the resources of a survey research center
experienced in all aspects of survey design
— questionnaire development, sample de-
sign, informed consent and clearance pro-
cedures. Implementing the design required
staff experienced in interviewer recruitment
and training and field management of data
collection in dispersed localities, ranging from
massive urban cores to remote rural enclaves.
Delivering the data required resources for
data-entering and cleaning information sub-
mitted on hard copy instruments, and for
preparation of final data files accessible to
analysis. Completing the data analysis re-
quired an expert in policy and clinical issues
regarding treatment services, and an econo-
mist with general expertise in assessing the
costs and benefits of problem behaviour and
specific knowledge of drug treatment deliv-
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ery systems in the U.S.. NORC undertook
to complete all tasks under a U.S. $2.2 mil-
lion contract, which included subcontracting
the cost/benefit analysis. The necessary staff
included Dr. Gerstein as overall director, a
sampling statistician, a statistical programmer,
a project manager with operational respon-
sibility for instrument design, data collection,
data preparation, and budget management,
a field project manager with a subordinate
staff of five field managers overseeing sev-
enty field interviewers, and a director of field
training, with administrative support from
NORC’s financial centre and technical sup-
port from its centre for information services.
Henrick Harwood conducted the economic
analysis; he was co-author a few years pre-
viously with Dr. Gerstein of a major national
study, sponsored by the U.S. Department of
Health and Human Services, on drug treat-
ment policy and programs. A field office was
set up in Pasadena, near the residence of the
field project manager, to facilitate communi-
cations within the large state of California,
where the surveyed programs were as much
as 750 miles apart and more than 1800 miles
from NORC’s central office in Chicago.
How were the data
collected?
The CALDATA study was carried out in four
stages, 1992-1994: Stage 1 - Facility Sampling
and Program Director Interview; Stage 2 - Re-
spondent Sampling and Record Abstraction;
Stage 3 - Respondent Interviews; Stage 4 -
Analysis. The work in each stage is described
in more detail in the sections that follow.
Stage 1 - Facility sampling and
program director interview
Information in the CADDS database as of
September, 1992, provided the foundation
for the sample of drug and alcohol treatment
programs used by CALDATA. CADDS
included all providers who received any type
of public funding via ADP for treatment or
recovery services during the current or pre-
vious year, including grants, contracts, and
reimbursements from MediCal (the state
administered federally funded program of
medical care for the poor, the disabled, and
the near-poor).  State law required that they
provide key administrative data about their
programs and their participants in treatment.
For practical purposes, the CADDS data-
base yielded an exhaustive listing of drug and
alcohol treatment facilities in California.
Facility sampling proceeded in three stages,
under the direction of Dr. Robert A. Johnson.
The ultimate goal was selection of a group of
discharged participants that would yield data
applicable to the whole population of
participants discharged from publicly funded
drug and/or alcohol treatment facilities in
California in the sample year October 1,
1991 - September 30, 1992. CALDATA’S
respondents had to be clustered geographi-
cally to economise the costs of interviewer
travel. (California extends 1200 miles north
to south along the Pacific coastline, with
population concentrated in the southern two-
thirds, and 300 miles west to east beyond
the coast and the central valleys across thinly
populated mountains and deserts.) The re-
spondents had also to be related to the spe-
cific type of drug and alcohol treatment pro-
grams from which they were discharged, so
that outcomes could be studied in relation to
the kinds of services received and the set-
tings in which they were delivered. The sam-
pling team determined that at least 400 re-
spondents were needed to analyse
relationships between each type of treatment
program, or modality, and participant out-
come. Selection of a multi-stage probability
sample met the sampling goals. Statistical ac-
countability required that each member of the
population of participants discharged in the
sample year be given a known chance of
selection, equalised to the extent possible
within the strata of locality and treatment
modality. At each stage, sample members
received numerical weights reflecting the
variation from random choice created by
clustering and stratification.
To ensure appropriate geographical cover-
age, the 58 counties in California were first
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discriminated into five groups—Los Ange-
les County, the San Francisco Bay Area,
Southern Urban, Central Valley, and Moun-
tain/Rim counties. Because of the size of their
treatment systems, six highly urbanised
counties were selected with certainty: Los
Angeles, San Francisco, San Diego, Orange,
Alameda, and San Bernardino. Selection of
10 further counties proceeded by associat-
ing the counties with smaller numbers of par-
ticipants in recovery with geographically
neighbouring counties with larger numbers of
participants. The final county selection was
made from these county clusters, so that
Fresno, Kern, Riverside, Sacramento, San
Mateo, Santa Clara, Solano, Stanislaus,
Tehama, and Ventura counties were added
to the six certainty counties.
The final stage of program sampling applied
the modality principle—selection according
to type of treatment program— to facilities
in the 16 selected counties. Based on
CADDS data, five distinctive treatment mo-
dalities were designated. Four modalities
were to be sampled for participant discharges
only, while the fifth had added a subsample
of participants in treatment. Treatment set-
tings, services, and characteristic population
served varied among modalities:
Residential treatment - Facilities of-
fering residential services with a variety
of drug and/or alcohol treatments.
Social model recovery - Residen-
tial treatment plans specially developed
in California that provide 31 days or more
of recovery/ treatment services to alco-
hol users in small programs that stress
peer support and communal approaches.
Non-methadone outpatient - Fa-
cilities offering a variety of outpatient ser-
vices and treatment plans. Programs may
be large or small, and usually rely on psy-
chological counselling.
Methadone/Detox - Outpatient facili-
ties offering daily doses of methadone and/
or other prescribed medicines to support
planned withdrawal from heroin use, usu-
ally for short periods such as 30 days.
Methadone maintenance outpa-
tient - Facilities offering chemical main-
tenance and other non-residential services
for the opiate-dependent.
The CALDATA sampling plan worked with
totals of participants discharged from treat-
ment at its selected facilities in the course of
the sample year, October 1, 1991 - Sep-
tember 30, 1992. Because participants re-
ceiving maintenance doses of methadone
commonly remain in treatment for years, a
subsample of participants currently in treat-
ment at Methadone Maintenance Outpatient
facilities (the CMM sample) was added to
the study design.
NORC’s nationally distributed field staff,
with broad experience in social science re-
search, was a project asset. Five California-
based field managers joined Kay Malloy,
CALDATA’s California-based project field
manager, to make telephone contact with the
directors of the selected facilities, following
up on an advance letter from ADP. During
the initial phone contact, the field staff sought
to schedule a site visit from a CALDATA
abstractor and arrange a mailing of the
CALDATA Provider Questionnaire, an in-
strument that gathered basic administrative
and cost data about the facility. It was ex-
pected that most facilities would require in-
put from several staffers to complete the Pro-
vider Questionnaire. Individual questions
sought data that measured administrative and
staff turnover, qualifications of staff members,
space owned or rented by the facility, the
value of property and the cost of rentals,
annual costs of equipment, supplies, exter-
nal services, and volunteer services, annual
treatment revenues and public and private
insurance coverages for services, with unit
costs for various types of service. The data
collection plan called for an advance mailing
of the Provider Questionnaire to allow the
facility to research answers, followed by a
formal administration of the instrument by the
abstractor in the course of the site visit.
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Another important element in the campaign
to gain co-operation of the facilities was Dr.
Gerstein’s presentation to a meeting of Cali-
fornia directors of county alcohol and drug
treatment agencies, explaining the methods
and objectives of CALDATA. A free-flow-
ing question and answer session allayed their
numerous concerns about the approach to
respondents, the confidentiality of records
and privacy of respondents, and the uses
of the data, and gained the assistance of
many in reassuring other sampled provid-
ers concerned with participation in the study.
Two large chains of proprietary methadone
maintenance facilities represented the ma-
jor problem of provider enlistment, endlessly
deferring or categorically refusing appeals
for co-operation from field and project
staffers. When facility contacting had
concluded, the field staff reported an 85%
co-operation rate, scheduling site visits
covering 83 of the 97 selected providers,
which included 110 modalities of treatment.
Some facilities were selected for more than
one treatment modality; for example,
methadone providers commonly offered
maintenance as well as detoxification
services. Facilities sampled twice for par-
ticipant record abstraction were counted
only once for Provider Questionnaire col-
lection and site visit logistics. One of the 83
facilities withdrew from the study after
abstraction was completed.
While scheduling site visits, the field staff
worked energetically to recruit the required
records abstractors. Many of the 55 abstrac-
tors trained in November 1992 to complete
the sampling and abstraction phase of the
study were interviewers with experience on
other NORC studies, known to the field
management staff and consequently, re-
cruited. However, the sampling and abstract-
ing tasks at a CALDATA facility did not ap-
peal to some experienced interviewers who
preferred more traditional interviewing. In
contrast, individuals with backgrounds in
medical records abstraction or drug treat-
ment counselling were attracted to the
CALDATA work.
Confidentiality considerations also con-
strained staffing. If an employee of the re-
search team had a history of employment or
treatment at a local facility, especially one
selected for the CALDATA sample, it might
appear to facility staff or to respondents that
their information would circulate in the local
community. That belief, however ill-founded,
would compromise the candor of response.
All prospective abstractors, both experienced
and new to NORC, were screened for as-
sociations with California treatment facilities,
either in staff or participant roles. Only those
without any ties to local treatment facilities
were employed.
Respondent sampling and
records abstraction
A two-day training session introduced the
CALDATA abstractors to procedures for
listing and selecting a random sample of dis-
charged participants and for working with
facility records to abstract data about each
selected participant. Besides practising with
sampling procedures and materials, abstrac-
tors practised with the two CALDATA ab-
straction instruments, the Participant Ab-
straction Record (PAR) and the Participant
Locating Record (PLR). They were also
trained on confidentiality principles and pro-
cedures, on managing their relations with fa-
cility staff, and on administering the Provider
Questionnaire.
The Participant Abstraction Record was
designed to capture analytical data about the
sampled treatment episode and about prior
participant history from administrative
records. The PAR requested data on basic
demographic characteristics, sources of pay-
ment for treatment, and living arrangements
at admission. Other PAR items included
sections on arrest and imprisonment, medi-
cal history, alcohol and drug history, drug test
results, prior treatment, services received,
discharge status, and charges for the sample
episode. Nothing in the PAR permitted iden-
tification of the individual. The Participant
Locating Record, by contrast, was designed
to facilitate locating. Most of the PLR was
41Workbook 5  •  Cost Evaluations
WHO/MSD/MSB 00.2f
given over to date of birth, Social Security
Number, address and telephone number,
driver’s license, and other official numbers
associated with the selected participant, in-
cluding additional names and contact data on
employers, relatives, friends, professional
staff, and other treatment facilities.
The abstractors worked with sampling rules
for each facility extrapolated from the infor-
mation in CADDS. Sampling rates varied
according to the size of the facility and were
designed to yield an average of about 30
selected participants per sampled facility.
Each modality at a facility had a set of sam-
pling rules designed for it, furnished to the
abstractor on a computer printout. A sam-
pling interval, like Take each third discharge
starting with listed discharge #2, pre-
scribed the selection rate and the random
choice. The printout also described upper
and lower limits for total number of discharges
in the sample year. The limits of one-half or
double the expected number were designed
to insure that the number of discharges in the
list created on-site by the abstractor corre-
sponded within an acceptable range to the
information reported to CADDS. When the
total of listed discharges fell outside the lim-
its, the abstractor phoned the NORC sam-
pling department, which provided an ad-
justed sampling procedure.
In some facilities, sampling proceeded quite
smoothly. However, many abstractors dis-
covered discharge totals that fell above the
upper limit given in their sampling rules. Since
the CADDS database from which the sam-
pling rates were derived was new and con-
tained less than one year’s worth of data,
the twelve-month discharge estimate for each
program had been developed by projecting
a straight line from the number of months of
discharges that were thought to be reflected
in the database. The actual 12-month list of
discharges proved to exceed the estimate
derived from CADDS by a factor of two or
more in 31 of the 87 co-operating modali-
ties. Overall adjustments were required to
protect the integrity and statistical properties
of the sample design, and also to keep the
number of selected participants within the lim-
its of the data collection budgets.
When the participant sample was success-
fully selected at a facility, abstraction from
program records with the PAR and the PLR
usually proceeded without major difficulties.
There were field stresses because abstrac-
tors found it difficult to work efficiently in many
facilities. The drug and alcohol treatment
programs were open at irregular or inconve-
nient hours and their staffs, preoccupied with
their own work, often could provide only
minimal assistance to the abstractors. Work-
ing space was cramped and improvised, and
abstractors were forced to develop self-suf-
ficiency at interpreting program record sys-
tems and finding the required data in partici-
pant records. A common disappointment for
abstractors was absence in the record of
much of the detail needed for locating, on
which success in finding the selected partici-
pant for interview in Phase 2 of the data col-
lection depended. A number of completed
PLRs had scant identifying detail; sometimes
even the participant’s name was borrowed
from fiction or folklore, like Scaramouche or
Humpty Dumpty.
At the close of Phase 1, data collection
CALDATA had selected and abstracted data
for 2,746 discharged participants at 87 co-
operating modalities, with an additional Con-
tinuing Methadone Maintenance (CMM)
participant sample of 309 selected at 12 of
the Methadone Maintenance facilities. (Four
modalities were found ineligible at site visit
because they discharged no participants in
the sample year.) Adjusting for a handful of
abstractions determined to be duplicates, a
total of 3,045 respondents were to be sought
for the Participant Interview. The 19 eligible
modalities that refused co-operation repre-
sented 31,529 participant discharges in the
sample year. Adjusted for participants lost
from uncooperative providers as well as for
missing records at co-operative providers,
the Phase 1 participant abstraction comple-
tion rate was 76.5%. Table 1 on the follow-
ing page summarises Phase 1 sampling and
facility co-operation.
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Collecting completed Provider Question-
naires, the final Phase 1 CALDATA data
collection activity required a good deal of time
and patience in the field. The requested in-
formation was not readily available at many
facilities. Several different facility staffers
were often needed to complete the question-
naire appropriately, and their responsiveness,
indeed their perception of responsibility for
the document, was confused and variable.
Diplomacy and persistence eventually pro-
duced a completed Provider Questionnaire
from 76 of the 82 facilities that contributed
to the participant sample.
Respondent interviews
In Phase 2 of the CALDATA data collec-
tion, the field staff was increased to 70 inter-
viewers who were assigned the tasks of lo-
cating the 3,045 selected participants,
explaining the study and securing their co-
operation, and administering the Discharged
Participant or Continuing Methadone Ques-
tionnaire as appropriate. The questionnaires
were designed for a face to face interview
averaging 1.5 hours.
The interview for discharged participants
was structured around sharply defined sec-
tions covering experiences before, during,
and after a sample treatment. After pre-
liminary questions about the respondent’s
ethnic and educational background, the
questionnaire repeated in three time frames
a series of questions about drug and alco-
hol use, mental and physical health, ille-
gal activities and criminal status, living
arrangements and family, employment, and
drug and alcohol and mental health treat-
ments. A calendar designed for use with
the questionnaire graphically displayed the
three time segments for which behaviour
questions were repeated: the 12 months
just prior to the sampled treatment episode,
the time span of the sample treatment, and
the time elapsed since the sampled treat-
ment episode.  The questionnaire incor-
porated design features common to a num-
ber of large-scale drug outcome surveys
under development at the time. The ques-
tionnaire used to interview the participants
in continuing methadone maintenance (the
CMM Questionnaire) was a modified ver-
sion of the Discharged Participant Question-
naire. CALDATA Field Managers carried
out a pretest of the questionnaire, the calen-
dar, and procedures for explaining the study
with 32 respondents in January/February
1993 that was particularly concerned to
TABLE 1:  CALDATA phase 1 response rates by modality
Sample providers 19 23 27 19 18 106 18
Participants in target pop. 21,409 6,699 50,963 49,500 8,296 136,867 9,741
Co-operating providers 18 21 23 13 12 87 12
Participants
represented in co-
operating providers 20,370 6,079 40,034 32,940 5,916 105,338 6,946
Response rate based
on co-operating providers 95.1% 90.7% 78.6% 66.5% 71.3% 77.0% 71.3%
Indicator Discharge sample modality  Total Total
 discharge CMM
 sample sample
 Residential Social  Outpatient       Methadone       Methadone
model  Non-meth. Detox maintenance
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test respondents’ ability to focus on time seg-
ments and keep information within the ap-
propriate time frames, and interviewers’ abil-
ity to keep the respondent on track through
repetitive sets of questions.
In March, 1993, a three-day training intro-
duced the CALDATA interviewers to the
Participant Questionnaires. In addition to
scripted practice with their instruments, in-
terviewers practised with protocols for ap-
proaching respondents, including a long
script prescribed by the California Commit-
tee for the Protection of Human Subjects
explaining the purposes of the study, its vol-
untary nature, and the confidentiality with
which all information was held.  A field pro-
cedures manual laid down the steps in con-
tacting and locating respondents, beginning
from the principle that CALDATA inter-
viewers were never to explain the research
except as a “health study” until they were
secure that they were speaking to a selected
respondent in private.
Training in field procedures drew upon the
32-person pretest. The field managers con-
ducting the pretest had found their small
group of pretest respondents dramatically
more difficult to locate than respondents for
research on issues like job market behaviour
or health care expenditure. Once located, the
pretest respondents as a group had been
difficult to bring to the point of interview—
evasive, suspicious and prone to break ap-
pointments. Hence the CALDATA inter-
viewer training prepared the field staff for
special difficulty in contacting and locating,
suggesting that patience, persistence, and a
strong positive attitude from the interviewer
would eventually reassure a respondent.
Confidentiality protocols and issues were
another training emphasis: interviewers’ suc-
cess in gaining the co-operation of
CALDATA participants and gathering
valid data from them depended above all
on giving them confidence that their an-
swers would in truth be held in utmost pri-
vacy, used only for research, and published
only as summary statistics. To assist the
field staff in making such assurances, the
study obtained a Confidentiality Certificate
from the U.S. Department of Health and
Human Services that shielded the interview-
ers from legal action that might require them
to testify in court about the whereabouts or
criminal activity admissions of respondents.
At conclusion of training, each interviewer
received an initial assignment of about 30
cases. As expected, a proportion of respon-
dents was located and interviewed fairly
quickly, but many others were harder to pin
down. To get word to this group, interview-
ers were encouraged to distribute a distinc-
tive blue business card with the neutral name
used in fielding CALDATA and the toll-free
phone number of the project’s California of-
fice in the course of their locating inquiries.
Word was circulated among friends and con-
tacts of the respondents that they were
sought for a health study, and that a check
in payment was due them. The project staff
believed that the distinctive card would
enhance the visibility of the study in the
drug using communities with which respon-
dents had contacts. If it were generally
acknowledged in the local drug cultures
that the “health study” was legitimate
unthreatening research with a payment of
$15, hesitant respondents could be won
to call up the office and make appoint-
ments for interview. Consequently, about
400 respondents called the toll-free phone
number.
In addition to circulating the card with the
office phone number, the project instituted
locating procedures with local agencies. A
regular weekly check of a new-inmates jail
list circulated by Los Angeles County (site
for one-fourth of the sample) effectively lo-
cated a number of respondents. The Cali-
fornia state prison system endorsed the study
and facilitated contacts with respondents in
state prisons. Commercial databases giv-
ing recent addresses for persons using
credit cards were accessed at modest cost.
Computerised telephone directories were
employed by field managers to track re-
spondents with distinctive names to dis-
tant communities or to look for relatives who
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might have recent contact. ADP arranged for
inquiries about respondents’ addresses with
the California Department of Motor Vehicles,
which maintains a huge database showing the
addresses to which drivers’ licenses and well
as motor vehicle registrations are issued. The
California Department of Social Services
could not by statute divulge address infor-
mation but agreed to search its large data-
base of welfare recipients and to circu-
late a “health study” letter asking for phone
contact to any respondents discovered.
The various database searches contributed
significantly to the success of the data col-
lection, but CALDATA staff found that the
persistent, patient, unthreatening personal
inquiries of interviewers were indispens-
able to the final outcome. Interviewers who
could inspire confidence while maintain-
ing patience and masking their eagerness
to push the inquiry to a final result made
the difficult contacts with homeless and
all but nameless respondents.  During the
records abstraction, staff of facilities treat-
ing numbers of homeless people had as-
serted that CALDATA would never find and
interview their discharged participants. But
interviewers did find a reasonable number (49
of 121 assigned cases with no address in-
formation for the respondent or any relative
or associate were successfully interviewed).
The interviewers used every avenue open to
them and were inventive about developing
their own locating procedures, like blending
into the background and lingering at centers
maintained for the homeless or in drug-deal-
ing areas in metropolitan cities until someone
answered a casual question and furnished a
clue to a missing respondent.
At close of the nine-month Phase 2 field
period, 1821 respondents, 61.4% of the
eligible participant sample, had completed
the interview. Table 2 summarises the
Phase 2 data collection by modality. Sev-
enty-seven participant cases were ineli-
gible, assigned a final Out of Scope sta-
tus. Fifty-seven of these had died since the
treatment episode 8 spoke neither English
nor Spanish and could not be interviewed
(CALDATA developed a Spanish transla-
tion of the Discharged Participant Inter-
view but was not prepared to gather data
in other non-English languages). Eight were
physically or mentally incapacitated to the point
that they could give no interview and four were
ineligible for other reasons.
TABLE 2:  CALDATA final participant case status counts by modality
 Modality type  Original Out of Net Completed No %
 sample scope  sample interview complete
1- Social Model Recovery 703 9 694 401 293 57.8%
2- Methadone Detox 474 24 450 294 156 65.3%
3- Nonmethadone Outpatient 641 11 630 382 248 60.6%
4- Residential Treatment 615 15 600 343 257 57.2%
5a- Methadone Maintenance Outpatient 302 13 289 182 107 63.0%
5b- Continuing Methadone Maintenance 310 5 305 219 86 71.8%
TOTALS 3045 77 2968 1821 1147 61.4%
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One thousand one hundred forty-seven eli-
gible participants were not interviewed.
Two hundred thirty-one of this group, 7.8%
of the eligible net sample, were contacted
and refused to give an interview. Such a
percentage of refusals is well within ac-
ceptable range for most surveys. Five hun-
dred ninety-two of the non-interview cases,
19.9% of the net sample, could not be lo-
cated in the course of the nine month field
period. This percentage loss would not be
expected in a population under no special
stress. Given the population that CALDATA
interviewers attempted to contact, and the
uneven quality of identifying information,
this loss rate is not surprising.
Besides the refusals and unlocatables, the
other non-interview cases were participants
who had been located, but for one reason or
another interviews had not been arranged.
Small groups were in jails, prisons, or
treatment centers that did not allow inter-
viewer access. Seventy cases had been
traced outside the borders of California
but could not be reached to arrange a tele-
phone interview (An interview over long
distance phone was CALDATA’S standard
approach to remotely located respondents.
Altogether, 119 interviews were com-
pleted by phone.). Fifty-two non-interview
cases had been located in California but
had broken appointments, often repeatedly.
Time ran out on this group. The general
CALDATA experience with evasive, slow
to convince respondents suggests that many
in the broken appointment group would
have given an interview had the deadline
not halted field work. The final non-inter-
view group represented 185 respondents
who were known to be welfare clients in
California. Towards the end of the field
period the Department of Social Services
forwarded letters to them describing the
health study and giving the project office
phone for contact. Phone calls in response
to the mailing were just beginning to come in
to the project office as data collection ended.
Indeed, the final 33 interview documents
reached NORC’S central office too late to
be included in data processing and were set
aside from the analysis. Had the field period
been longer a number of the 185 welfare
cases would have completed interviews.
A final component of CALDATA Phase 2
data collection was the Validation
Reinterview, organised to confirm the cir-
cumstances that interviewers reported when
they submitted completed questionnaires.
Such validation is routinely built into data
collection plans employing in-person inter-
views with dispersed samples. Survey re-
search interviewers seeking to conduct in-
terviews at the convenience of randomly
selected, scattered respondents necessarily
work very independently. For CALDATA
NORC, field managers took weekly phone
reports of case status and field costs from
interviewers and transmitted the results to
central office. Completed questionnaires
received a quality control edit at the
project’s California office and their receipt
was then communicated to central office.
Objective verification of at least ten per-
cent of each interviewer’s completed
cases with a brief telephone Validation
Reinterview was required. The
reinterview instrument confirmed that the
interview took place with the sampled re-
spondent when and where reported,
checked the time elapsed, and verified
content by re-asking a few innocuous data
items. The validation process turned up
one suspect interviewer when a sample
respondent denied answering the question-
naire, asserting that he had refused to make
an appointment when requested. The vali-
dation staff undertook a systematic review
of the suspect interviewer’s entire com-
pleted caseload, and eventually determined
to replace every interview. When valida-
tion of all interviewers’ work was com-
pleted, 346 cases had responded to vali-
dation reinterview, a validation rate of
19% of the completed caseload of 1821,
systematically distributed in early, middle, and
late field period.
When Phase 2 data collection ceased on
December 1, 1993, the large task of data
preparation began. This meant cleaning and
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data entering the information from Provider
Questionnaires, Participant Abstraction
Records, Discharged Participant Question-
naires, and Continuing Methadone Mainte-
nance Questionnaires. As part of on-going
quality control during the field period, the
project office in California had given prelimi-
nary edits to the PQs, the PARs, and the
Discharged Participant Questionnaires. On
receipt at NORC’s central office the instru-
ments received a full edit, with coding of se-
lected items in the Participant Questionnaire,
before entry at computer terminals using a
Computer Assisted Data Entry Program with
Autoquest software. Range and consistency
checks for individual items were pro-
grammed into the software. Additional con-
sistency or logic checks were added to the
program by project staff.  Quality control of
data entry included a random re-keying of
10% of each operator’s work by a second
operator. After data entry, hard copy case
materials were filed by case ID in the library
maintained by NORC’s data preparation fa-
cility. The final data files were delivered on
diskette to the project team responsible for
the analysis. Dean Gerstein, Robert. A.
Johnson, and Natalie Suter of NORC
worked with Henrick J. Harwood and Dou-
glas Fountain of Lewin-VHI, Inc., subcon-
tractor for the cost/benefit analysis, to com-
plete the report to ADP.
How were the data
analysed?
The analytical team first inquired into the
strengths and limits of the data. In Phase
1, the field staff had successfully completed
work at 87 of 106 eligible modalities for
an 82% modality completion rate. In Phase
2, the field had interviewed 60.9% of 3,045
sampled participants in time to meet the
data preparation deadline. Were the result-
ing data sufficient to represent the whole
population of participants discharged from
publicly supported treatment in the sample
year in California, plus the population in con-
tinuing methadone maintenance? The partici-
pant completion rate was the product of the
rate for participants represented in the Phase
1 abstraction times the rate for the partici-
pants data-entered from Phase 2, 60.9% of
76.5%, or 46.5%. Could the analysis pro-
ceed to discuss the effects and costs of drug
treatment in California, looking at informa-
tion that represented less than half of the par-
ticipant sample? Answering this question
meant separate consideration of sample bias
due to provider non-response and partici-
pant non-response.
Bias due to provider non-response was not
equally distributed among modalities. Tak-
ing into consideration the number of dis-
charged participants represented by success-
ful abstractions, the Phase 1 completion rate
was greater than 90% for the Residential and
Social Model modalities, greater than 75%
for the Outpatient Non-Methadone modality,
and less than 75% for the Methadone Detox
and Methadone Maintenance modalities
(See Table 1, page 42). The lower co-op-
eration rate from methadone programs
stemmed from refusals of owners of two
large chains of methadone facilities oper-
ating for profit. To get some idea of the
bias created by the relatively light sample
of methadone providers, the analysts
looked outside their CALDATA files. In
the fiscal year before the CALDATA
sample was drawn, California had re-
ported on a number of participant and pro-
vider characteristics to the National Drug
and Alcoholism Treatment Unit Survey
(NDATUS), conducted by the National In-
stitute on Drug Abuse. A comparison be-
tween CALDATA and NDATUS was run
for participant age, sex, and ethnicity, and
for the weekly work hours of several kinds
of professional staff at facilities. Both for
residential and methadone providers, the
CALDATA and NDATUS participant data
were broadly similar. The data about pro-
fessional staff levels in the two sorts of pro-
grams were likewise similar. The compari-
son with NDATUS suggested that bias in
CALDATA results due to provider non-co-
operation might not be severe.
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To study the characteristics of participants
whose data were missing because they had
been sought but had not been interviewed
during Phase 2 of data collection, the ana-
lysts had another resource—the data ab-
stracted in Phase 1 from provider records
into the Participant Abstraction Record. For
most measures there was no difference be-
tween sampled respondents and sampled
non-respondents. Where differences were
statistically significant, a lack of data at the
PAR item often seemed responsible. For
example, participants described as His-
panic—Mexican Americans or other Ameri-
cans reporting ethnic derivation from Span-
ish America—represented 37% of
CALDATA respondents and 30% of non-
respondents. But the Hispanic variable was
missing in more than 20% of PARs for both
respondents and non-respondents. This sug-
gested data distortion from item non-re-
sponse rather than a systematic difference
between respondents and non-respondents.
The overall conclusion from the comparison
of PAR data was that the Phase 2 respon-
dents could reasonably be taken as repre-
sentative of the whole population of sampled
discharged participants in CALDATA’s
sample year. It appeared that Phase 2 par-
ticipant non-response depended primarily on
poor quality address and other locating in-
formation obtained from provider records,
and the quality of locating information in the
provider record seemed largely independent
of the characteristics and treatment outcomes
of discharged participants.
The CALDATA analysts also considered the
strengths and the possible limits of the de-
sign implicit in the Discharged Participant
Questionnaire. The questionnaire asked
about repeated categories of experience
in three time segments—the 12 months be-
fore treatment, time during sampled treat-
ment, and time since treatment. The data
items permitted measurement and compari-
son of the behaviour of the same individual
before and after treatment, or pre/post com-
parison. Pre/post comparison allows the
analyst to use sampled participants as their
own controls. Participant characteristics
which tend to have a permanent influence on
behaviour, like gender, ethnicity, personal
appearance, early experience and upbring-
ing, and other aspects of character and per-
sonality, are held constant in comparisons of
experiences pre- and post treatment. If there
appear to be treatment effects, such back-
ground characteristics can be ruled out as
causes. To get comparable controls for the
sampled group using another sort of research
design, it would be necessary to match each
participant with a drug user not in treatment
who had the same background characteris-
tics—a sampling exercise of impossible com-
plexity. The CALDATA design had another
advantage for analysis. When statistical mea-
sures indicated pre/post treatment changes
in the sample, the analysis could identify in-
dividuals who had changed and seek to de-
scribe the ways in which certain sub-groups
who changed behaviour differed from each
other and from other sorts of participants
whose behaviour did not change.
In designing CALDATA to allow pre/post
comparison, the analytical team relied on re-
spondents’ ability to recall and report details
of their behaviour over several years with
reasonable accuracy. The sample year be-
gan with discharges on October 1, 1991,
while the last Phase 2 interviews were con-
ducted in November, 1993. The maximum
retrospective recall for 12 months pre-treat-
ment extended over something more than
three years. Given the familiar experience,
that some people cannot routinely recall
events a week in the past, was the research
team justified in expecting high quality retro-
spective recall from its participant sample?
The pretest of the Discharged Participant
Questionnaire conducted by field managers
in January/February 1993 had sought to test
sampled participants’ ability to recall and to
discriminate between past events in the three
time frames. The results from that small
sample indicated that administration of the
questionnaire was indeed feasible. But as
responsible students of behavioural change
over time, the CALDATA analytical team felt
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obliged to address questions about the kind
and degree of measurement error involved
in retrospective recall when they examined
their final data. They considered five pos-
sible sources of error:
Recall delay - People have progres-
sively greater difficulty remembering
events, the more remote they are in time.
CALDATA sought to minimise this source
of inaccuracy by limiting recall to recent
time. Questions focused on behaviour of
high personal interest, more likely to be
recalled than monotonous routines. The
study’s best safeguard against recall de-
lay came from the fact that recall delay
would minimise reporting that suggested
beneficial treatment effects.
Telescoping - This measurement er-
ror derives from people’s tendency to
assign events to an earlier or later time
period than the one in which they oc-
curred. CALDATA sought to minimise
telescoping by repeatedly focusing re-
spondents’ attention on the reference pe-
riod of each question and by associating
the beginning and end of each period with
memorable events like admission to and
discharge from treatment. To the extent
that evidence of treatment effectiveness
appeared in the data, it could be consid-
ered stronger for having risen above any
error created by telescoping.
Under reporting of sensitive
behaviours - It is common wisdom that
people are more likely to suppress re-
sponses that implicate them in criminal
behaviour or otherwise tend to cast
shame on them, such as having sex for
money or drugs, armed robbery, diag-
nosis as HIV-positive, or use of drugs
and alcohol. But participants dis-
charged from drug treatment do not re-
act to such questioning with the sponta-
neous alarm that might be expected of the
general population. The research team
knew that if CALDATA respondents
could be reassured that they would incur
no damage in answering they would re-
port illegal and illicit behaviour. Earlier
drug research studies had run compari-
sons between self-reported illicit drug use
and drug test results that showed respon-
dent reporting was valid. In interviewer
training CALDATA emphasised non-
judgemental management of the interview,
unbiased probing techniques, and confi-
dentiality guidelines.  Also, because the
analysts knew of research showing that
Under reporting is most common for sen-
sitive events in the present or the near past,
they did not rely on respondent reports of
current illicit behaviour only, but based
analyses on periods of 12 months or longer.
Reversion to more typical
behaviour - Earlier studies of drug
treatment had shown that participants use
more drugs and alcohol and commit more
crimes, often related to the need to sup-
port a drug habit, in the time period just
before admission to treatment.  Indeed
the high levels of substance abuse and
related deviant behaviour are factors that
induce participants to seek treatment.
Thus CALDATA’s analysis needed to be
careful that it did not describe as a treat-
ment effect changes caused by reversion
to more typical behaviour.  The year-long
recall periods built into its data tended to
smooth out pre-admission jumps in devi-
ant behaviour. The analytical team agreed
that small changes revealed by pre/post
comparisons should be set aside as pos-
sibly influenced by reversion to more typi-
cal behaviour, but that reversion was a
negligible issue when changes were large.
Differential non-response - A fi-
nal bias in the data might arise because
more participants whose treatment was
beneficial co-operated with CALDATA
than participants whose treatment was
not. The analysts studied their PAR data
and Non-Interview Reports on refusal
cases and found little evidence of bias
from this source. Those who rejected
the study tended to come from more se-
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cure backgrounds, to have more finan-
cial and social resources, and to live in
more comfortable circumstances post-
treatment than those who co-operated.
Having reviewed potential sources of data
distortion and satisfied themselves that the
study design compensated appropriately for
them, the analysts proceeded to run pre/post
comparisons of data for reported respondent
behaviour in the areas covered by the re-
peated sections of the Discharged Partici-
pant Questionnaire, testing changes for sta-
tistical significance using standard methods.
Analysing the cost and benefits of treatment
called for use of measures derived from thirty
years of research into the economics of drug
treatment. Economic impacts of participant
behaviour were calculated by measuring its
negative drain on the overall economy, off-
set by values contributed by participant em-
ployment. When post-treatment economic
impacts were less than the cost of treatment
itself, a benefit was judged to exist, and when
they exceeded the cost of treatment, a loss
was declared. This cost/benefit analysis dis-
tinguished costs to society as a whole from
costs to taxpaying citizens. Costs to Society
include losses of society’s net productivity
or losses in society’s net wealth. Thus,
participants who do not earn up to their po-
tential because of drug and/or alcohol abuse
represent negative economic impacts, as do
the costs of health services, police forces,
and corrections facilities deployed because
of participants’ drug use and related crimes.
However, the values of goods or cash stolen
by participants, and of welfare and disability
payments they receive, do not count as costs
but as transfer payments, in which money sim-
ply moves from one pocket to another
within the society as a whole. Costs to
Taxpaying Citizens include only those
losses to individuals in society who do
not engage in any substance abusing
behaviour. For these people, the loss of
earnings from drug- or alcohol-dependent
participants who are not living up to their
potential is of little concern, while the value
of goods and cash stolen by substance
abusers is a serious cost, as is money ex-
pended on welfare and disability payments
made to drug and alcohol abusers.
What did they
find out?
CALDATA analysts calculated the costs
related to participants’ criminal behaviour
and health care utilisation and the value of
their labour force productivity by assign-
ing average values to each criminal act,
arrest, incarceration, health care
utilisation, earnings, and welfare/disabil-
ity reported by participants, factoring in
data from current statistical compilations
such as the Sourcebook of Criminal Jus-
tice Statistics and Hospital Statistics.
Cost of participants’ sampled drug treat-
ments was based on data from
CALDATA’s Provider Questionnaire aug-
mented by CADDS data. The State of Cali-
fornia spent $209 million in treating the
146,609 participants represented by
CALDATA’s discharged and continuing
methadone samples. The average treatment
for the 136,867 discharged participants
lasted 95 days and cost $1,361. Residen-
tial treatment was substantially higher in
cost than outpatient treatment—$61.47 per
day, $4,405 per episode for the Residen-
tial modality, vs $7.47 per day, $990 per
episode for the Nonmethadone outpatient
modality.
The analysis found that benefits to tax-pay-
ing citizens during the time participants were
in treatment and in their first year post-treat-
ment represented approximately 1.5 billion
in savings, due mostly to reductions in crime.
Each day of treatment paid for itself—the
benefits to taxpaying citizens equaled or ex-
ceeded costs—on the day it was received.
Table 3 summarises the pre/post compari-
son of costs both to taxpaying citizens and
to society (Earnings totals are bracketed as
productive inputs counting against the other
negative impacts).
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The benefits of alcohol and other drug treat-
ment outweighed the costs of treatment by
ratios from 4:1 to greater than 12:1 depend-
ing on the type of treatment. For the whole
society, the cost-benefit ratios ranged from
2:1 to more than 4:1 for all modalities except
for methadone maintenance outpatient.
The analysis supported the hypothesis that
treatment was effective in changing partici-
pant behaviour. The level of criminal activity
declined by two-thirds from before treatment
to after treatment. Declines of approximately
two-fifths occurred in the use of alcohol and
other drugs from before treatment to after
treatment. About one-third reductions in
hospitalisations were reported from be-
fore treatment to after treatment, with corre-
sponding significant improvements in other
health indicators. Treatment for problems with
the major stimulant drugs was as effective as
treatment for alcohol problems and some-
what more effective than treatment for heroin
problems. For each type of treatment stud-
ied, there were slight or no differences in ef-
fectiveness between men and women,
younger and older participants, or among
African-Americans, Hispanics, and Whites.
Overall, treatment did not have a positive
effect on the employment of participants. The
most common source of income for partici-
pants before and after treatment was full-time
employment. Welfare, illegal activities, and
disability payments were the next most com-
mon income sources. Rates of employment
and income from employment were both
generally lower post-treatment than pre-
treatment. Overall employment earnings de-
clined by 29%. This finding is consistent with
the depressed economic trend in California
1991-1993. In every type of treatment, more
participants enrolled in disability programs
TABLE 3:  CALDATA costs
Pre/Post Treatment Total Dollar Costs   Dollar Costs Per Person
Year Before Year After Year Before Year After
Criminal Justice System $1,086,043,000 $841,800,000 $7,935 $ 6,151
Victim Losses 524,727,000 310,387,000 3,834 2,268
Theft Losses 815,738,000 253,297,000 5,960 1,851
Health Care Costs 441,698,000 337,923,000 3,227 2,469
[Earnings] [1,378,105,000] [1,101,356,000] [10,069] [8,047]
Lost Earnings 2,343,151,000 2,619,912,000 17,140 19,164
Income Transfers 250,466,000 275,563,000 1,830 2,013
Costs to Taxpayers $3,118,672,000 $2,018,971,000 $22,786 $14,751
Costs to Society $4,395,447,000 $4,109,605,000 $32,151 $27,035
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and participants received more money in dis-
ability payments after treatment, increases
ranging from one-sixth to one-half. The
analysis indicated that treatment increased eli-
gibility for disability payments even though it
led to overall improvements in health status.
The cost-benefit analysis concluded that par-
ticipants in the California treatment system
reduced their criminal activity and health care
utilisation during and in the year following
treatment by amounts worth well over $1.4
billion, for an overall ratio of benefits to costs
of 7 to 1. Savings included reduced criminal
justice expenses (police protection, adjudi-
cation, and corrections), reductions in victim
losses (stolen and damaged property, inju-
ries, and lost work), and lower levels of health
care utilisation (hospitalisations, emergency
room use, outpatient care.) Savings were
offset by modest increases in welfare and dis-
ability dependence.
How were the
results used?
Dr. Mecca released CALDATA’s findings
at two back-to-back press conferences in
September 1994 in San Francisco and Los
Angeles. The report received extensive na-
tional press coverage and was influential
in altering U.S. perceptions of the effec-
tiveness and social value of drug and al-
cohol treatment. The fact that the study was
brought to fruition so quickly while perti-
nent national studies were not yet ready
for release was to its advantage. The White
House Office of National Drug Control
Policy and other federal agencies have ref-
erenced the study and it is routinely cited
in academic research into drug treatment
and mental health evaluation.
CALDATA continues to yield results. Further
analysis of the data has been supported by
the Office of the Secretary of the U.S. De-
partment of Health and Human Services and
by the Robert Wood Johnson Foundation, one
of the largest health-oriented philanthropies in
the U.S. The March 1996 A Treatment Pro-
tocol Effectiveness Study issued by General
Barry R. McCaffrey, Director of the White
House Drug Office, cited CALDATA as a
major source of evidence for its White Paper
on treatment effectiveness. Federal spending
on drug treatment increased by over 17 per-
cent between fiscal year 1994 and fiscal year
1996; the increase was over 25 percent when
one compares 1994 with the federal budget
request for the fiscal year 1998.
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Its your turn
What are the strengths and the weaknesses of the presented case example? List three posi-
tive aspect and three negative aspects:
Strengths of the case study
1
2
3
Weaknesses of the case study
1
2
3
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